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The overall goals of basic research in improving the clinical approach to a disease are, on the 
one hand, to unravel its natural history, finding its cause and developing better treatments and, 
on the other hand, to find biomarkers that would permit to ameliorate the diagnosis, to 
distinguish among patient subtypes and to set up clinical trials of new therapeutic agents. The 
common threads of the two projects developed in this thesis are the technique used, 
proteomics, and the main object, Parkinson‟s disease (PD). Proteomics is a powerful 
methodology to investigate how protein expression is affected in the pathogenesis of a disease 
process and should be exploited both to investigate PD pathogenetic mechanisms and to 
discover peripheral biomarkers. 
In the first part of this thesis the project “A SH-SY5Y model to investigate PD pathogenetic 
mechanisms” is discussed. We investigated the expression pattern of cellular proteins 
following dopamine exposure in catecholaminergic SH-SY5Y human neuroblastoma cells 
overexpressing α-synuclein by a proteomic approach. Using 2D gel image analysis and 
ANOVA statistics we identified proteins that correlate with the experimental conditions in our 
model. Significant changes in specific cellular processes were observed, such as cytoskeleton 
structure and regulation, mitochondrial function, energetic metabolism, protein synthesis and 
neuronal plasticity. Proteins were analyzed by a network enrichment tool that automatically 
enriched the network model in terms of the most relevant proteins that seem to be missing. 
Moreover, the bioinformatic approach found out the enriched Gene Ontology (GO) 
categories, allowing us to draw attention to the NF-κB pathway. To validate experimentally 
the hypothesis of the NF-κB involvement, we performed a luciferase gene reporter assay that 
revealed a downregulation of the transcription factor activation by α-synuclein increased 
expression and its complete quenching by dopamine exposure.  
Each element arising from the present study could represent a valuable starting point for 
focused investigations aimed to better understand key issue of PD pathogenesis. For instance, 
a protein that completely disappeared after dopamine treatment was VDAC2, a porin of the 
outer mitochondrial membrane. Since the impairment of mitochondrial function is considered 
among the major pathogenetic factors of neurodegeneration in PD, we further investigated the 
regulation of VDAC2 degradation and the role of its phosphorylation.  
Accumulating evidence supports a specific role of DJ-1 in protecting dopaminergic neurons 






different function and localization, we analyzed DJ-1 2D electrophoresis pattern in SH-SY5Y 
cells after exposure to dopamine; we observed a specific increase in the most acidic forms in 
the pattern together with a significant decrease of the most basic spot. Unlike cells exposed to 
generic oxidative conditions, no additional shift was observed. The results are corroborated by 
a meta-analysis of the literature showing that in the absence of dopamine treatment the 
specific acidic form is underrepresented.  
The second part of the thesis is focused on the project “Dopamine response of dopaminergic 
circulating cells: the Jurkat cell model”. The functions of immune cells are regulated not only 
by cytokines, but also by several neurotransmitters. In particular, peripheral blood 
lymphocytes possess a complex dopaminergic regulatory system. Human T-lymphocytes 
express all five dopamine receptors (D1-D5), each of which exerts different actions on the 
regulation of T-cell functions. The Jurkat human leukemia CD4+ T-cell line has been 
thoroughly used and characterized as a suitable cell model to investigate T-cell signaling and 
apoptosis, nevertheless its characterization as a model of circulating dopaminergic cells was 
never reported before. In this regard, we characterized the dopaminergic system in Jurkat cells 
and through a proteomic approach we analyzed their response to a dopamine challenge in 
order to highlight metabolic pathways that could specifically reveal alterations linked to PD. 
A dopamine challenge, with no effect on cell viability (50 µM), induced quantitative changes 
in the protein expression pattern. The proteins that showed quantitative differences were 
identified by peptide mass fingerprinting and analyzed in terms of both interaction network 
and GO classification enrichment. We obtained a significant model for network enrichment 
and a functional association to GO classification (unfolded protein binding). Eventually, we 
observed a modification of β-actin and 14-3-3 two-dimensional pattern following dopamine 
exposure.  
In both projects, by combining the experimental and the bioinformatic approach, we fulfilled 
the expectations for proteomics to generate new hypotheses. Of course, one must consider 
that models have limitations and that hypotheses need further validation, but they could be a 












1.1 The proteomic approach to investigate pathogenethic 
mechanisms and to find biomarkers for Parkinson’s disease 
 
The overall goals of basic research in improving the clinical approach to a disease are, on the 
one hand, to unravel its natural history, finding its cause and developing better treatments and, 
on the other hand, to find biomarkers that would permit to ameliorate the diagnosis, to 
distinguish among patient subtypes and to set up clinical trials of new therapeutic agents.  
Dealing with neurodegenerative disorders with a complex etiology and a still obscure 
pathogenesis, it is difficult to generate valuable hypotheses and set up focused investigation to 
reveal new insights of the disease. This would require an a priori speculation on probable 
causes and pathological cascades that follow. Being the subject of interest a multifactorial 
condition such as it is the case of Parkinson‟s disease (PD), the choice of a biased approach is 
often a dead-end strategy.  
Consequently, a recent effort has focused on the use of –omics techniques, i.e., 
transcriptomics, proteomics, and metabolomics, in order to elucidate many of the pathogenic 
aspects of PD. As a matter of fact, a more comprehensive investigation of PD and the 
identification of specific disease networks and molecular pathways involved herein will 
facilitate our understanding of the disease process and enhance our ability to diagnose and 
treat this debilitating condition. In general, these techniques can be applied to various 
biological media, including tissues, cerebrospinal fluid (CSF), blood and blood constituents, 
urine, as well as others (Caudle et al., 2010).  
Proteomics is a powerful methodology to investigate how protein expression is affected in the 
pathogenesis of a disease process, providing a complement to the information obtained by 
functional genomics (see Hanash, 2003). Proteomics is a technology-driven approach, and 
takes advantage from unprecedented advances in separation techniques such as two-
dimensional electrophoresis and liquid chromatography, in the design and exploitation of 
high-sensitivity sources and analyzers for mass spectrometry, and bioinformatics (Tao and 
Aebersold, 2003). These advances have allowed the quantitative analysis of protein levels and 
post-translational modifications that altogether help to understand molecular alterations in 
cells, tissues and biofluids that are associated to disease etiology, progression, outcome, and 
response to therapy. On the other hand, proteomics provides a high-throughput methodology 
for the search of new therapeutic targets for diseases with a high social impact like cancer and 






term proteome was first introduced (Wasinger et al., 1995) to describe the entire protein 
complement of the genome in a given compartment at a given time. Proteomics also has the 
main goal to understand protein localization, modification, trafficking, interactions, and 
eventually function. This wealth of information cannot be obtained by genomics and 
transcriptomics alone, since the actual function of a gene depends on the activity of the 
translated, processed protein (Lee, 2003). The emerging field of neuroproteomics promises to 
provide powerful strategies to further characterize neuronal dysfunction and cell loss 
associated with neurodegenerative diseases (Becker et al., 2006; Fasano and Lopiano, 2008).  
Although the proteomic approach in neuroscience research is very recent, several papers have 
been published in the last four years on the investigation of pathogenetic mechanisms of 
neurodegenerative disorders by proteomics (Fasano et al., 2007; Fasano and Lopiano, 2008; 
Schulenborg et al., 2006; Sheta et al., 2006). Moreover, the field of clinical proteomics is 
especially well suited for the discovery of biomarkers; indeed, proteins that show 
reproducible changes either in levels or in post-translational modifications are potential drug 
targets or disease biomarkers. The latter are particularly useful if they are present in body 
fluids, like blood (plasma and blood cells) or urine, which are easy to obtain (Dorsey et al., 
2006; Fasano et al., 2008b; Sheta et al., 2006; Michell et al., 2004). 
Altogether, the proteomic methods are a valuable toolbox for either the analysis of 
pathogenetic mechanisms in neurodegenerative disorders and (cell and animal) models 
thereof, or the search for suitable biomarkers that should be useful for early and differential 
diagnosis as well as for therapy assessment. For these reasons, this thesis is focused on the 
two main goals of neuroproteomics mentioned above, in order to better understand the main 
actors of PD pathogenetic mechanisms and to reveal possible protein responders to dopamine-
related alterations at T-cells level. 
 
1.2 Parkinson’s disease  
 
Parkinson's disease is a neurodegenerative disorder characterized by motor symptoms 
(tremor, bradykinesia and rigidity) that develop as a consequence of the degeneration of 
dopaminergic neurons of the substantia nigra pars compacta (SNpc) (Thomas and Beal, 
2007). No single causative factor has been yet identified for PD, which may originate from 






formation of reactive oxygen species (ROS) and aberrant protein aggregation (Van Laar and 
Berman, 2009).  
The traditional view of PD as a single clinical entity is under scrutiny. Clinically, the disease 
is heterogeneous, and subtypes may be recognized on the basis of age of onset, predominant 
clinical features and progression rate. Two major clinical subtypes exist: a tremor 
predominant form that is often observed in younger people, and a type known as “postural 
imbalance and gait disorder” (PIGD) that is often observed in older people (>70 years old) 
and is characterized by akinesia, rigidity, and gait and balance impairment. In very general 
terms, the first subtype leads to a slow decline of motor function, whereas the latter worsens 
more rapidly (Obeso et al., 2010). Different clinical subtypes of PD are distinguished due to 
predominant motor symptoms: a tremor-dominant type (TDT), an akinetic rigid type (ART), 
and a predominant postural instability and gait difficulty (PIGD) type. Several studies suggest 
that the different subtypes may have different patterns of disease progression: whereas motor 
function deteriorates more rapidly in ART, it has a more benign course in TDT (Jankovic et 
al., 1990; Roos et al., 1996). The development of PIGD becomes a major cause of disability 
and dependence (Shulman et al., 2008). A different neuropathological substrate for these 
subtypes of PD has also been described (Jellinger et al., 1999). Patients with TDT have been 
reported to have less depression and cognitive deterioration (Lewis et al., 2005). A recent 
SPECT study of cerebral dopamine transporters revealed significant differences between TDT 
and ART at the same stage of PD (Spiegel et al., 2007). Patients with PIGD suffer 
significantly more from orthostatic hypotension than TDT patients (Allcock et al., 2006). 
Although Parkinson‟s disease is classically diagnosed by the onset of motor manifestations, 
the concept of premotor Parkinson‟s disease has gained support (Hawkes et al., 2008; 
Langston, 2006). There is increasing evidence that olfactory dysfunction, sleep abnormalities, 
cardiac sympathetic denervation, constipation, depression and pain may antedate the onset of 
motor signs of Parkinson‟s disease (O‟Sullivan et al., 2008). Affected nondopamine neurons 
include monoaminergic cells in the locus coeruleus (Zarow et al., 2003) and raphe nuclei, 
cholinergic cells in the nucleus basalis of Meynert (associated with cognitive deficits) (Hilker 
et al., 2005) and the pedunculopontine tegmental nucleus (which may be related to gait 
problems) (Rinne et al., 2008), and hypocretin cells in the hypothalamus (which likely 
mediate the sleep disorders seen in Parkinson‟s disease) (Thannickal et al., 2007). 
Approximately 30–50% of these nondopamine cells have been lost by end-stage Parkinson‟s 






reflects the stepwise progression of Lewy body (LB) pathology in the brain. These authors 
have suggested a caudorostral gradient of LB formation from the lower brainstem to the 
neocortex (Braak et al., 2006). This suggests that once the disease has started, there is a single 
progression wave, and that the onset of dementia, generally late in the course of Parkinson‟s 
disease, is due to cortical LB  (Braak et al., 2005).  
LB are mainly composed by α-synuclein and extensively ubiquitinylated proteins; these 
intracytoplasmic inclusions are also immunoreactive for 3-nitrotyrosine and neurofilament 
(Devine and Lewis 2008; Thomas and Beal 2007). Histological evidence shows that the more 
pigmented neurons are the first ones to degenerate, suggesting thus that neuromelanin 
depletion does not occur at random (Hirsch et al., 1988); conversely, it has been reported that 
the less pigmented ventral tier of SN is the first to degenerate in PD, with a more extended 
cell loss with respect to heavily pigmented regions (Gibb, 1992; Kastner et al., 1992). It has 
been proposed that neuromelanin, that confers the dark pigmentation to dopaminergic 
neurons, may act as a scavenger of redox-active transition metals and of toxic catechol 
intermediates (Fedorow et al., 2005; Youdim et al., 1994; Zecca et al., 2003). Other factors 
that may selectively affect SNpc neurons compared to other catecholaminergic cells include 
differences in their handling of ionic fluxes -less capacity for calcium buffering (Esteves et 
al., 2010) and increased reliance on L-type calcium channels (Chan et al., 2007)- and in their 
expression of specific transcription factors that regulate cell fate and survival (Alavian et al., 
2008). Currently, there is no definitive explanation for why these abnormalities affect 
dopaminergic neurons earlier and more profoundly than other cell types. One major common 
theme for most mutations and toxins is the impairment of mechanisms related to cellular 
energy production leading to oxidative stress. It may be that the selective vulnerability of 
nigrostriatal cells is determined by their profuse arborization, which may result in high levels 
of energy consumption. It has been estimated that nigrostriatal dopaminergic neurons can 
form as many as 40,000 synapses, whereas neurons in the ventral tegmental area only make 
up to 3,000 contacts. It is known that aging decreases energetic cellular efficiency as well as 
the synthesis and activity of neuronal growth factors. This could explain the enhanced 
vulnerability with aging and even the trend toward reduction of regional vulnerability. Dietary 
habits and lifestyles associated with reduced risk of Parkinson‟s disease (for instance, 
smoking, coffee drinking, and diets high in uric acid or greater levels of physical activity in 
midlife) could somehow modify the cellular processes affected in the pathology and reduce 






1.2.1. Epidemiology and Genetics 
 
PD affects over 1% of the population above the age of 65 but early onset PD (EOPD) patients 
develop symptoms before age 50 years (Schrag and Schott, 2006; Lesage and Brice, 2009). 
EOPD patients have an increased likelihood of a genetic etiology of the disease compared 
with patients with late-onset PD, however it has been suggested that also late-onset PD may 
have a substantial familial component (Payami et al., 2002; Kay et al., 2006). 
About 10-15% of patients with the typical clinical picture of PD have a positive family 
history compatible with a mendelian (autosomal dominant or autosomal recessive) 
inheritance. As a rule, age at onset in many (but not all) of these patients is younger than that 
of patients with sporadic disease, but no other specific clinical signs or symptoms distinguish 
familial from sporadic cases (Gasser, 2009). Although the different mutations and loci 
identified so far appear to be directly responsible in only a relatively small number of families 
each, there is accumulating evidence that the molecular pathways identified may be common 
to more than one genetic form of PD and may also play a role in the common sporadic disease 
(Gasser, 2009). 
Autosomal recessive forms of parkinsonism are linked to mutations in parkin (PARK2, the 
most common), PINK1 (PTEN-induced putative kinase 1; PARK6), DJ-1 (PARK7), 
ATP13A2 (PARK9), PLA2G6 (PARK14) and FBXO7 (PARK15) genes, and are characterized 
by age at onset usually before 40 years. As for the autosomal dominant forms, mutations in 
five genes have been identified:-synuclein (PARK1 and PARK4), UCHL1 (ubiquitine C-
terminal ligase L1; PARK5), LRRK2 (leucine-rich repeat kinase 2; PARK8), GIGYF2 
(PARK11) and OMI/HtrA2 (PARK13) (Lesage and Brice, 2009; Gasser, 2009) (see Table 1).  
The most common monogenic cause of EOPD is due to mutations in the parkin gene on 
chromosome 6q. The disease is autosomal recessive, and numerous mutations in parkin have 
been described to date. About half of all patients with familial PD with onset before age 45 
years and a family history compatible with autosomal recessive inheritance have composite 
mutations in the parkin gene, and it causes about 10–20% of apparently sporadic cases with 
onset before age 45 years (Schrag and Schott, 2006, Lesage and Brice, 2009).  
The PARK8 gene encodes for dardarin (LRRK2). Different LRRK2 mutations have been 
described, with the G2019S mutation, a founder haplotype in several European populations, 
being found in up to 5-6% of several large cohorts of families with PD-affected members and 






epidemiology of LRRK2-related PD have yet to be fully elucidated, but mutations are present 
in various populations (Schrag and Schott, 2006; Gasser, 2009). Most patients have onset 
above age 50 years, and penetrance seems to be age related (Schrag and Schott, 2006). 
Nonetheless, several cases of EOPD are associated with LRRK2 mutations, including a recent 
report of a mutation in a 28-year old with apparently sporadic disease (Kay et al., 2006). 
Additionally, some cases of apparently idiopathic EOPD may also be due to either very rare 
and atypical genetic abnormalities, or to as yet unidentified genetic defects (Schrag and 
Schott, 2006).  
 
Table 1: Loci, genes and susceptibility factors involved in parkinsonism. 
 
PARK loci Form of PD GENE 
PARK1 EOPD AD  α-synuclein (mut) 
PARK2 Juvenile and EOPD AR  Parkin 
PARK3 LOPD AD SPR (?) 
PARK4 EOPD AD  α-synuclein (dupl./tripl.) 
PARK5 LOPD AD? UCHL1 
PARK6 AR  PINK1 
PARK7 EOPD AR DJ-1 
PARK8 LOPD AD and sporadic LRRK2, dardarin 
PARK9 Juvenile AR Kufor–Rakeb syndrome and EOPD  ATP13A2 
PARK10 non-Mendelian ? 
PARK11 LOPD AD GIGYF2 
PARK12 non-Mendelian ? 
PARK13 AD OMI/HtrA2 
PARK14 AR, Juvenile AR levodopa-responsive dystonia-
parkinsonism 
PLA2G6 
PARK15 AR, EO AR parkinsonian-pyramidal syndrome FBXO7 
 
EO, early-onset; LO, late-onset, AD, autosomal dominant; AR, autosomal recessive; PD, Parkinson‟s disease; PINK1, 
PTEN-induced kinase 1; LRRK2, Leucine-Rich Repeat Kinase 2; SPR, sepiapterin reductase; UCHL1, ubiquitin carboxy-
terminal hydrolase; GIGYF2, GRB10-interacting GYF protein 2; PLA2G6, group VI phospholipase A2 (adapted from 






1.3 Alteration of dopamine homeostasis and oxidative stress 
 
Oxidative stress is classically defined as a redox imbalance with an excess formation of 
oxidants or a defect in antioxidants. Although the body in general has developed several 
defense mechanisms to counteract oxidative stress, the brain appears to be more susceptible to 
this damage than any other organ, as it consumes about 20% of the resting total body oxygen. 
The ability of the brain to withstand oxidative stress is limited because of the presence of high 
amounts of polyunsaturated fatty acids, low levels of antioxidants such as glutathione(GSH) 
and vitamin E and the elevated content of iron in specific areas such as the globus pallidus 
and the substantia nigra (Chinta and Andersen, 2008). Moreover, being postmitotic, neurons 
in the brain once damaged may be permanently dysfunctional (Calabrese et al., 2005). Post-
mortem studies on brains from PD patients have consistently implicated the role of oxidative 
damage in the pathogenesis of PD. It is not clear whether accumulation of ROS in PD is a 
primary event or a consequence of other cellular dysfunctions (Chinta and Andersen, 2008). 
There is much evidence to suggest that ROS derived from the combined presence of 
dopamine (DA), low GSH, and high iron are a major cause of the loss of dopaminergic cells 
in the brains of individuals with PD (Jenner and Olanow, 1996; Youdim and Riederer, 1997). 
The metabolism of dopamine gives rise to various molecules that can act as endogenous 
toxins (Dodson and Guo, 2007; Lotharius and Brundin, 2002; Zhang et al., 2000). Indeed, 
dopamine is chemically unstable and can auto-oxidize at neutral pH with the formation of 
quinone species and hydrogen peroxide, which can be reduced into cytotoxic hydroxyl 
radicals in a reaction catalyzed by iron, whose levels are higher in SNpc than in other brain 
regions, oxygen, or enzymes such as tyrosinase (Barnham et al., 2004; Chinta and Andersen, 
2008; Lotharius and Brundin, 2002; Zecca et al., 2001). The electrophilic quinones 
themselves can act as oxidants thus supporting ROS formation. Auto-oxidation of dopamine 
may be increased in the early stages of the disease when dopamine turnover is increased to 
compensate for dying dopaminergic neurons (Scherman et al., 1989). Other dopamine 
metabolites such as 3, 4-dihydroxyphenylacetic acid (DOPAC) can undergo further two-
electron oxidation to generate ROS and DOPAC-quinones (Gluck and Zeevalk, 2004).  
Many of the genetic factors linked to PD lead to an impairment of dopamine homeostasis by 
interfering with the vesicular storage and release mechanisms. Dopamine auto-oxidation in 
the cytosol determines oxidative stress conditions that are magnified by the impairment of the 






Lopiano, 2008; Gasser, 2009; Lesage and Brice, 2009; Maguire−Zeiss et al., 2005; Thomas 
and Beal, 2007). 
Normally, ROS are eliminated by intracellular antioxidant systems, which might be impaired 
as a result of the aging process or in disease states. Although GSH is not the only antioxidant 
molecule reported to be altered in PD, the magnitude of GSH depletion appears to parallel the 
severity of the disease and is the earliest known indicator of nigral degeneration, reportedly 
preceding detectable losses in both mitochondrial complex I activity and striatal dopamine. 
GSH depletion has been demonstrated to result in complex I inhibition (Chinta et al., 2007). 
Depletion of GSH has also been reported to result in inhibition of glutathione reductase 
activity (the enzyme which converts oxidized glutathione or GSSG into reduced GSH) via 
direct oxidation of its two active site cysteine residues. This would result in further increases 
in GSH loss and alteration of the cellular redox state as the GSH/GSSG ratio is further 
decreased.  
These data indicate that not only can complex I inhibition result in increased dopamine 
oxidation, but dopamine oxidation itself might affect complex I function leading to 
mitochondrial dysfunction (Chinta and Andersen, 2008). 
Studies with toxins able to induce parkinsonian syndromes in experimental models further 
suggest a possible role for free oxygen in selective loss of SN dopaminergic neurons in the 
disease. For instance, 6-hydroxydopamine (6-OHDA) is known to destroy dopaminergic 
neurons through free radical-mediated mechanisms. Similarly, 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)-induced impairment of the mitochondrial respiratory chain via 
inhibition of complex I enhances superoxide formation that then can initiate neuronal death 
(Liu et al., 2010).  
As a whole, in a disease where the etiology is still unknown, many of the genetic and 
environmental factors variously linked to it contribute to a redox imbalance that seem to have 
the strongest effect on the more sensitive dopaminergic SN cells. 
1.4 α-Synuclein 
 
Mutations in the α-synuclein gene have an historical relevance as responsible for the first 
monogenic PD form identified. Three single point mutations, duplication and triplication of 
the gene were reported and linked to familial forms of Parkinson‟s disease (PARK1 and 
PARK4, respectively – see Table 1) (Gasser, 2009). α-Synuclein, a small 14 kDa protein, is a 






other proteins such as the 14-3-3 chaperonin, an anti-apoptotic factor that antagonizes α-
synuclein and shares 40% sequence conservation with the N-terminal region of α-synuclein 
(Goedert, 2001; Ostrerova et al., 1999; Spillantini et al., 1997). Early studies revealed that 14-
3-3 binds to and activates tyrosine hydroxylase (TH) (Ichimura et al., 1988), the rate-limiting 
enzyme in catecholamine synthesis. α-Synuclein, like 14-3-3, may also bind to TH but, in 
contrast, inhibits its activity (Perez et al., 2002). This finding suggests that a loss of α-
synuclein by its aggregation or its decreased expression, as occurs in PD, may selectively 
disrupt DA homeostasis and negatively impact dopaminergic neuronal survival (Perez et al., 
2002). 
As explained in Paragraph 1.3, oxidative imbalance is supposed to be the main pathogenetic 
event in triggering neurodegeneration in PD. α-Synuclein can variously contribute to 
oxidative stress. Expression of either wild-type or mutant protein in different cell lines has 
demonstrated that α-synuclein modulates DA toxicity, associated to reactive oxygen species 
(ROS) arising from DA oxidation (Fasano and Lopiano 2008; Wood-Kaczmar et al., 2006;) 
(see Figure 1). Several studies indicate that α-synuclein protofibrils can modify the 
permeability of vesicles by formation of pores similar to those generated by pore-forming 
bacterial toxins (Lashuel et al., 2002; Volles et al., 2001; Volles  et al., 2002). The altered 
membrane permeability could cause unregulated calcium flux and leakage of DA into the 
cytoplasm that leads to cell death (Lotharius and Brundin, 2002, Volles et al., 2001;) (see 
Figure 1). DA quinone reacts with α-synuclein to form covalent adducts that slows the 
conversion of protofibrils to fibrils (Conway et al., 2001). This finding suggests that cytosolic 
DA in dopaminergic neurons promotes the accumulation of toxic α-synuclein protofibrils, 
which might explain why these neurons are most vulnerable to degeneration in PD (Rochet et 
al., 2004). Cross-linking promoted in vitro by DA-derived radicals was already suggested to 
occur in neurofilament subunits and several other proteins (Hao et al., 2007; Montine et al., 
1995). Noteworthy, evidence for cross-linking of α-synuclein to oxidized, polymerized DA 








Figure 1: Dopamine, α-synuclein and neurodegeneration Dopamine (DA), either 
synthesized or reuptaken from synaptic space (1), is stored into vesicles by the 
vesicular monoamine transporter (2), so that the concentration of cytosolic DA is 
kept low. Cytosolic DA is auto-oxidized to yield dopamine quinone (DAQ) (3) and  
eventually forms neuromelanin (NM) (4), α-Synuclein (α-Syn) may cross-link with 
the growing NM polymer to yield a melanoproteic adduct (5), or aggregate into 
soluble protofibrils (6) able to form pores through the membrane of vesicles and 
consequently to release stored DA (7); eventually, α-Syn protofibrils assemble 
together with other proteins to form Lewy bodies (LB) (8). Adapted from Fasano 
and Lopiano, 2008. 
 
PD-characteristic aggregates of α-synuclein have been found not only in the central nervous 
system (CNS), but also in the enteric nervous system, that is connected to the CNS via the 
vagal nerve. According to the pathogenetic hypothesis proposed by Braak and coworkers, as 
already explained in Paragraph 1.2, α-synuclein progressively accumulates in the brain 
starting from defined induction sites (medulla oblongata/pontine tegmentum and olfactory 
bulb/anterior olfactory nucleus) and advancing in a topographically predictable sequence, 
with motor symptoms becoming appreciable only when α-synuclein starts to assemble into 
the very first LB in SNpc melanized neurons (Braak et al., 2004).  
The role of α-synuclein in cell death is unclear as is the form the protein has when it causes 
cell death. α-Synuclein conformation can range from unfolded state in solution, to α-helical in 






Fasano and Lopiano, 2008). The presence of  LB within cells has been taken as an indication 
that toxic α-synuclein acts intracellularly to initiate apoptotic pathways, but the viability of 
cells with aggregated forms of α-synuclein suggests that these cells are resistant to the toxicity 
of this form of the protein. This leaves to the possibility that intracellular α-synuclein is only 
toxic under certain conditions (Brown, 2010). Aggregates of α-synuclein can take on a variety 
of forms. Most commonly noted are the fibrillar forms of the protein. Other forms include 
oligomeric species and small protofibrils. These alternative forms of aggregates can take on 
distinct forms such as rings or stellate spheres (Wright et al., 2009). The conditions under 
which these different aggregates form is, therefore, of considerable importance. The most 
reliable factor in this regard is molecular crowding (Uversky, 2002). The higher the 
intracellular concentration of α-synuclein, the more likely it is to form aggregates. 
Considerable evidence suggests that oligomers, formed as prefibrillar intermediates, may be 
the toxic component (Danzer et al., 2007; Karpinar et al., 2009; Outeiro et al., 2008; Volles et 
al., 2001; Wright et al., 2009). Studies of aggregation using recombinant α-synuclein lead to 
the investigation of factors that increase the rate or extent of aggregation. One of the factors 
identified was the presence of metal ions (Uversky et al., 2001). In particular, copper has been 
shown in numerous studies to greatly enhance the aggregation of α-synuclein (Brown, 2010 ).  
There are clear evidences that high levels of α-synuclein can be damaging, but it is equally 
true that raising the level of the same protein from low to moderate is beneficial (Quilty et al., 
2006). Cookson proposed a J shaped model to explain the dual role of α-synuclein (Figure 2; 
Cookson, 2006). At low levels, lack of α-synuclein is detrimental for cell viability, and there 
is a moderate amount of expression where synuclein expression maximally improves neuronal 
viability (many of the toxins that are commonly used to generate experimental parkinsonian 
syndromes – rotenone, MPP
+
, 6-hydroxydopamine and dopamine itself – all increase α-
synuclein expression), which tails off as expression levels increase above the doubling seen in 
the genomic triplication. If a neuron forms an inclusion body and deposits fibrillary α-
synuclein into an insoluble Lewy body, then the probability of the cell survival is improved. It 
is worth stressing that the concentration responses have narrow ranges. In this vision, the 
normal function of α-synuclein is partially neuroprotective and the upregulation seen in 
chronic neurodegenerative diseases is a deliberate action on the part of the neuron to protect 
itself. Clearly, it becomes central to understand normal functions of this protein to better 
explain this phenomenon. Indeed, whether synuclein is toxic or beneficial will depend on 








Figure 2: α-Synuclein's J-shaped curve. The relationship between α-synuclein and 
cell survival is complex and involves a number of factors including time, amount of 
expression and neuronal phenotypes. This schematic representation emphasizes the 
effects of α-synuclein expression levels on cell survival. Moderate expression levels 
(moving towards the centre of the x-axis) seem to promote cell survival, but high 
expression levels are associated with pathological events including inclusion body 
formation and cell loss (towards the right of the same axis). It is also important to 
note that some of these events seen at high expression levels can be dissociated from 
each other. To show this schematically, the two lines diverge at higher expression 
levels. A current, if controversial, hypothesis in the field is that more soluble forms 
of α-synuclein are toxic. These are represented as oligomers and pore-like annular 
structures and would be associated with cell death. An alternative route is that α-
synuclein can form fibrils and be deposited into inclusion bodies (Lewy bodies 
shown here). While this may come at the cost of decreased function, this may also 








DJ-1/PARK7 is an ubiquitous, highly conserved protein that was originally identified because 
of its ability to transform NIH3T3 mouse cells in cooperation with Ras (Nagakubo et al., 
1997). Starting from the association between loss-of-function mutations in the DJ-1 gene and 
PARK7, a monogenic, autosomal-recessive form of PD (Bonifati et al., 2003), an 
accumulating body of evidence pinpointed the important role of DJ-1 in this 
neurodegenerative condition. Very recently, it has been shown that oxidized dopamine can 
covalently modify DJ-1 (Van Laar et al., 2009); however, whether this can affect dopamine 
cell degeneration is unknown. Some hints may come from the involvement of DJ-1 into many 
cellular functions, including evidence linking this protein to oxidative stress response – a fact 
well known even before the association of DJ-1 with PD (Mitsumoto et al., 2001) – 
mitochondrial function (Zhang et al., 2005) and transcription (Zhong and Xu, 2008), nuclear 
transcription (Xu et al., 2005), mRNA binding and protein interaction (Hod et al., 1999; Van 
der Brug et al., 2008) and protein degradation (Xiong et al., 2009). 
Mirroring the involvement of DJ-1 in multiple cellular activities, this protein has been found 
in complex with multiple molecular partners, including DJ-1 itself (Tao and Tong, 2003), 
PINK-1 and Parkin (Xiong et al., 2009), alpha-synuclein (Meulener et al., 2005), HSP70 (Li 
et al., 2005), DJBP (Niki et al., 2003), PIASx alpha (Takahashi et al., 2001), ASK1 (Waak et 
al., 2009), histone deacetylase 6 (Olzmann et al., 2007), androgen receptor (Tillman et al., 
2007), DAXX (Junn et al., 2005), and Abstrakt (Sekito et al., 2005). 
DJ-1 has been shown to modulate dopamine toxicity in cellular models of oxidative stress 
with reference to PD (Fasano et al., 2008a; Kim et al., 2005). Dopamine exposure leads to 
upregulation of DJ-1 that in turn increases cell resistance to dopamine itself and reduces 
intracellular oxidants (Lev et al., 2008; Lev et al., 2009). On the other hand, α-synuclein 
overexpression leads to upregulation of DJ-1, and DJ-1 overexpression protects cells from α-
synuclein toxicity (Batelli et al., 2008; Colapinto et al., 2006; Zhou and Freed, 2005). Besides 
being in complex with a number of different partners, DJ-1 is often post-translationally 
modified. DJ-1 modifications mainly include oxidations at different sites, which is related to 
its antioxidant role (Choi et al., 2006; Kinumi et al., 2004; Mitsumoto et al., 2001), but there 
are also evidences of ubiquitination (Olzmann et al., 2004, Olzmann et al., 2007) and 






Not unexpectedly, DJ-1 binding to its molecular counterparts, and thus its pleiotropic effects, 
are affected by DJ-1 posttranslational modification. For example, oxidation regulates 
homodimerization (Ito et al., 2007) and affects DJ-1 binding to mRNA (van der Brug et al., 
2008), ASK1 (Waak et al., 2009), HSP70 (Li et al., 2005), parkin (Moore et al., 2005), while 
ubiquitination mediates the binding to histone deacetylase 6 (Olzmann et al., 2007). 
Multiple DJ-1 modified forms are simultaneously present, so that DJ-1 can be better 
considered as a pool of different forms, with different modifications and in different amounts. 
It is very likely that, instead of the total amount of DJ-1 or of a defined DJ-1 form, the 
composition of this pool and the precise balance between different forms is the main factor 
determining DJ-1 global activity (Alberio et al., 2010a). 
In particular, alterations of this pool, instead of DJ-1 mutations, are expected to play a role in 
those non-genetic conditions correlated to DJ-1 activity, including idiopathic PD. Indeed, 
since many different DJ-1 forms can be separated on the basis of their pI, it is a common 
finding that DJ-1 oxidation, correlated to ageing, Parkinson‟s and Alzheimer‟s diseases, 
produces an increase in DJ-1 species of acidic pH, and a decrease in basic species, so that 
these conditions are characterized by a pool of DJ-1 forms different than that observed in 
controls. Up to 10 different DJ-1 forms, including the acidic forms (pI 5.5 and 5.7) of DJ-1 
monomer and the basic forms (pI 8.0 and 8.4) of SDS-resistant DJ-1 dimer, were reported to 
selectively accumulate in PD and AD frontal cortex tissues compared with age-matched 
controls (Choi et al., 2006, Canet-Avilés et al., 2004, Meulener et al., 2006). Ubiquitination 
and SUMOylation of DJ-1, on the other side, affects also the molecular weight of the 
modified species, and are thus separated by mono-dimensional electrophoresis accordingly 
(Olzmann et al., 2004, Olzmann et al., 2007, Shinbo et al., 2006). 
 
1.6 Cellular models to investigate dopamine and α-synuclein toxicity 
 
Proteomic technologies have been widely used in the investigation of neuronal differentiation 
and neurodegeneration, particularly in the detection of differences between healthy 
individuals and patients suffering from neurodegenerative diseases. However, human tissue 
samples, while exceedingly important for studying neurodegeneration, are heterogeneous 
from patient to patient, which increases the difficulty of identifying changes in protein 
expression for a specific disease state. Another important point is that patient tissue samples 






collecting tissues undergoing disease development. To deal with this cellular complexity and 
to overcome heterogeneity and problems in sample collection, the use of cellular culture 
models has been considered (Johnson et al., 2005). Among the most frequently used 
continuous cell lines in neurobiology are SH-SY5Y, C-1300, NSC34, MES. 
As described in Paragraph 1.3, dopaminergic neurons are particularly exposed to oxidative 
stress because the metabolism of DA gives rise to various molecules that can act as 
endogenous toxins. On this basis several efforts have been made to develop cell models for 
dopamine toxicity. The majority of data about the degeneration of melanized dopamine 
containing neurons has come from animal and cell cultures studies that employ neurotoxins 
such as rotenone (Shastry, 2001) and 6-hydroxydopamine (6-OHDA), which replicate many 
characteristics of the parkinsonian syndrome. 6-OHDA is widely used because it selectively 
kills catecholaminergic neurons and induces cellular responses relevant to the naturally 
occurring disease such as mitochondrial dysfunction, oxidative stress and apoptotic death 
(Dauer and Przedborski, 2003, Marti et al., 2002, Walkinshaw, 1994). In any case, it would be 
advisable to explore the effects of misregulated dopamine homeostasis that is the most 
probable trigger of dopaminergic neuron death in sporadic PD, rather than those of toxins that 
act in a less specific way (6-OHDA) or target specific proteins (rotenone on mitochondrial 
complex 1). 
The catecholaminergic SH-SY5Y human neuroblastoma cell line is a valuable model to 
explore dopamine toxicity and its accumulation in the cytosol. Indeed, these cells express the 
DA transporter (DAT) and DA receptors and are able to form storage vesicles, although the 
low activity of the vesicular monoamine transporter type 2 (VMAT-2) impairs DA storage 
into vesicles. For this reason, SH-SH5Y cytoplasmic DA concentration may be raised by 
administering extracellular DA in the culture medium (Gomez-Santos et al., 2003). Moreover, 
addition of catalase is able to markedly improve cell survival (Colapinto et al., 2006) even in 
the presence of 1 mM DA, in agreement with a similar observation on PC12 cells (Blum et 
al., 2000). Thus, it is possible to investigate dopamine effects in these models, eliminating 
aspecific effects due to H2O2 generation in the extracellular space. 
Specific mitochondrial proteins covalently modified by dopamine and its oxidized form, 
dopamine-quinone, have been identified in rat isolated mitochondria and in SH-SY5Y cells, 
using a proteomic analysis (Van Laar et al., 2009). 
As explained in Paragraph 1.4, despite the association between α-synuclein and various 






death. Several authors increased the level of α-synuclein by transient or conditional 
expression, observing extensive protein aggregation and increased susceptibility to DA 
toxicity (Junn and Mouradian, 2002; Kanda et al., 2000; Lee et al., 2001; Tabrizi et al., 2000; 
Tanaka et al., 2001; Xu et al., 2002). Zhou et al. employed quantitative proteomics in 
conjunction with isotope-coded affinity tags (ICAT) to identify the proteins associated with 
soluble α-synuclein that might promote its aggregation (Zhou et al., 2004). More than 250 
proteins associated with Nonidet P-40 soluble α-synuclein were identified, and at least 51 of 
these proteins displayed significant differences in their relative abundance in α-synuclein 
complexes under conditions where rotenone was cytotoxic and induced formation of 
cytoplasmic inclusions immunoreactive to anti α-synuclein (Zhou et al., 2004). To 
characterize the exact biological role of α-synuclein other authors evaluated changes in whole 
genome expression in SH-SY5Y caused by reductions of 90% in α-synuclein RNA levels and 
of 59% in α-synuclein protein levels as a result of RNA interference (Häbig et al., 2008). The 
expression of 361 genes was altered, with 82 up-regulated and 279 down-regulated. The 
differentially expressed gene products are involved in the regulation of transcription, cell 
cycle, protein degradation, apoptosis, neurogenesis, and lipid metabolism. 
Wright et al. used SH-SY5Y cells to demonstrate the toxicity of α-synuclein oligomers. Only 
the aggregated protein generated in the presence of copper was toxic. Analysis with electron 
microscopy demonstrated that these oligomers were present only when α-synuclein was 
bound to copper (Wright et al., 2009).  
 
1.7 Parkinson’s disease as a mitochondrial disease 
 
Strong evidence now exists to support a role for aberrant mitochondrial form and function, as 
well as increased oxidative stress (see Paragraph 1.3), in the pathogenesis of PD (Schapira, 
2008). A complex interplay occurs between mitochondria and other cellular machinery that 
affects cell survival, as mitochondria not only have a key role in electron transport and 
oxidative phosphorylation, but they are also the main cellular source of free radicals, and they 
are involved in calcium homeostasis and in the regulation and instigation of cell-death 








Figure 3: Mitochondrial dysfunction affects diverse cellular processes that can 
culminate in cell death. Mitochondrial dysfunction affects a number of cellular 
pathways, leading to damage of intracellular components and to cell death. 
Abnormal metabolic function, abnormal morphology, and impaired fission–fusion 
balance have all been observed in mitochondria in at least some forms of Parkinson 
disease. Mitochondria are a major source of free radicals in the cell, resulting in 
oxidative stress, but mitochondria are also integral to the oxidative stress response. 
Increased oxidative stress can lead to impaired function of the UPS, thereby further 
affecting cell survival. Mitochondria also sequester calcium when intracellular 
calcium levels rise during the excitotoxic process. The threshold for excitotoxicity 
might decrease if mitochondrial ATP production is impaired. Mitochondria also 
have a pivotal role in apoptotic cell death. Mitochondrial release of cytochrome c 
and other „pro-apoptotic factors‟, such as AIF, into the cytoplasm triggers a cascade 
of events, culminating in cell death. Abbreviations: AIF, apoptosis-initiating factor; 
UPS, ubiquitin–proteasomal system (Henchcliffe and Beal, 2008). 
 
The most direct evidence for disrupted mitochondrial metabolism has come from studies of 
autopsy tissue and other tissue samples and in vitro cell cultures derived from patients with 
PD. The activity of complex I, a major component of the electron transport chain, is decreased 
in SN (Schapira et al., 1990) and frontal cortex (Parker et al., 2008) in patients with PD. 
Moreover, increased oxidative damage and reduced electron transfer rates through complex I 
subunits has been demonstrated in these individuals (Keeney et al., 2006). This abnormality is 
predicted to render cells more vulnerable to Bax-induced apoptosis and conceivably 
contributes to the dysfunction of cells during the PD disease process. Electron transport chain 
impairment might actually be systemic, as decreased complex I activity has been 
demonstrated in platelets (Haas et al., 1995), and defective oxidative phosphorylation has 






spectroscopy studies have demonstrated metabolic abnormalities consistent with 
mitochondrial dysfunction and a shift to anaerobic metabolism in vivo in humans with PD 
(see Henchcliffe et al., 2008). 
Several complex I inhibitors, such as MPTP, rotenone and paraquat, replicate some of the key 
motor features of PD and cause death of dopaminergic neurons. The precise role of 
environmental complex I inhibitors in PD remains to be defined, but the effect observed 
following complex I inhibitors help to corroborate concerns over other environmental toxins 
(Henchcliffe and Beal, 2008).  
Mitochondrial dysfunction leads to increased oxidative stress, which in turn induces α-
synuclein aggregation and impairs proteasomal ubiquitination and degradation of proteins 
(Jenner et al., 2003). 
Additionally, mitochondria have an integral role in the apoptotic cell death pathway; when the 
outer mitochondrial membrane is rendered permeable by the action of „death agonists‟, such 
as Bax, cytochrome c is released into the cytosol, leading to caspase activation and apoptosis 
(Green et al. 2004). Similar pathways are also activated by opening of the mitochondrial 
permeability transition pore, an event that can occur under conditions of oxidative stress or 
electron transport chain inhibition, leading to collapse of the mitochondrial membrane 
potential (Henchcliffe and Beal, 2008). 
The products of several PD-associated genes, including α-synuclein, Parkin, PINK1, DJ-1, 
LRRK2 and HTR2A, show a degree of localization to the mitochondria under certain 
conditions (see Figure 4). 
Oxidative damage to α-synuclein affects the protein‟s aggregation, an effect that might 
partially explain the cellular toxicity of the protein (see Paragraph 1.4). The α-synuclein 
protein contains an amino-terminal mitochondrial targeting sequence (Devi et al., 2008) and 
acidification of the cytosol or overexpression of α-synuclein can cause the protein to become 
localized to mitochondria (Cole et al., 2008; Devi et al. 2008). 
A number of mutations in the parkin gene (also known as PARK2) lead to autosomal 
recessive PD. Parkin acts as a ubiquitin E3 ligase within the UPS, and this activity is 
vulnerable to oxidative damage. Parkin also seems to have a fundamental role in 
mitochondrial function (Kuroda et al., 2006). In particular, very recently it was shown that 
parkin translocates to mitochondria upon dissipation of the mitochondrial membrane potential 
(ΔΨm) by the uncoupler carbonyl cyanide m-chlorophenylhydrazone (CCCP) or in response 






autophagic degradation (mitophagy). This year Geisler and coworkers unraveled that 
functional PINK1, a mitochondrial serine-threonine kinase that affords protection against 
oxidative stress, is a prerequisite to induce translocation of the E3 ligase parkin to depolarized 
mitochondria. In addition, the autophagic adaptor p62/SQSTM1 is recruited to mitochondrial 
clusters and is essential for the clearance of mitochondria. Strikingly, they identified VDAC1 
(voltage-dependent anion channel 1) as a target for parkin-mediated Lys27 poly-
ubiquitinylation and mitophagy. Moreover, pathogenic parkin mutations interfere with 
distinct steps of mitochondrial translocation, ubiquitinylation and/or final clearance through 
mitophagy. Thus, these data provide functional links between PINK1, Parkin and the selective 
autophagy of mitochondria, which is implicated in the pathogenesis of PD (Geisler et al., 
2010). Moreover, PINK1 acts with parkin to regulate the balance of mitochondrial fission and 
fusion (Yang et al., 2008). 
The leucine-rich repeat serine-threonine-protein kinase 2, LRRK2, associates, at least in part, 
with the outer mitochondrial membrane; its precise function in that location is unclear, but it 
is thought to interact with parkin (West et al., 2005). 
High temperature requirement protein A2, HTRA2, is a mitochondrial serine protease, the 
release of which might be involved in apoptotic cell death. Under conditions of oxidative 
stress DJ-1 is relocated to the mitochondrial matrix and intermembrane space acting there as a 








Figure 4: Products of PD-associated genes that affect mitochondrial function and 
oxidative stress. Acquired somatic mutations affect mitochondrial electron transport 
chain function, and such mutations are increased in the SN in patients with PD. Rare 
inherited mutations in genes encoding electron transport chain components have 
been associated with parkinsonism. Parkin, α-synuclein, PINK1, DJ-1, LRRK2 and 
HTRA2, are all encoded by nuclear genes, mutations in which can lead to PD, and 







1.8 Biomarkers for Parkinson’s disease  
 
In the absence of reliable and readily available laboratory tests, the diagnosis of PD is 
currently based on the clinical manifestations of the disease. Diagnostic features of PD are 
asymmetrical onset, rigidity, bradikynesia, unilateral tremor at rest and acute L-DOPA 
response (Jankovic et al., 2008). The picture is made more complicated by a large 
heterogeneity in terms of predominance of one of the motor symptoms over the others and in 




Figure 5: Peripheral biomarkers are required to accomplish different tasks: early 
diagnosis, possibly at a pre-motor stage; differential diagnosis of parkinsonian 
syndromes and of PD subtypes that may require different therapeutic plans; 
assessment of a personalized therapeutic plan; objective measurement of the actual 
extent of neurodegeneration so that neuroprotective and/or neurorestorative 






The availability of peripheral PD biomarkers would have a dramatic feedback. They would 
allow the differentiation of susceptible individuals from normal ones before motor symptoms 
appear (early diagnosis), and would help the identification of true idiopathic PD from atypical 
degenerative parkinsonisms (differential diagnosis). Moreover, the differentiation of patients 
in terms of their response to a pharmacological treatment would be possible (therapy 
assessment) (Michell et al., 2004). Eventually, biomarkers correlated to different PD subtypes 
would be an useful tools for the correct classification of PD patients so to start as soon as 
possible the appropriate therapeutic plan (Bogdanov et al., 2008) (see Figure 5).  
The onset of motor symptoms is a late event in the neurodegenerative process at the ground of 
PD (Braak et al., 2004); as a consequence, the search for potential biomarker candidates is 
usually performed on patients that show the clinical signs of the disease and therefore could 
not show any longer the presence of peripheral indicators occurring in the early stages of PD. 
Moreover, no protective or restorative therapies could be attempted at a stage when more than 
80% nigral neurons are lost (Dauer and Przedborski, 2003). On the other hand, it would be 
desirable to have available a panel of biomarkers that not only allow the diagnosis of PD at an 
early, pre-motor stage, but possibly correlate with the progression of the neurodegeneration 
progress. This would allow researchers to develop neuroprotective or neurorestorative agents 
and to follow directly their efficacy. Drugs that are now under clinical scrutiny as 
neuroprotective agents include molecules that combine one or more of the following 
properties: monoamine oxidase inhibition (e.g., rasagiline, safinamide), mitochondrial 
enhancement (e.g., coenzyme Q10, creatine), antiapoptotic activity, anti-inflammatory 
activity, protein aggregation inhibition, and neurotrophic activity (Bonuccelli and Del Dotto, 
2006). Although this is still far from actuality, clinical trials on new PD treatments cannot be 
foreseen in the absence of affordable biomarkers.  
The discovery of new PD markers should basically tackle two main objectives: the 
identification of molecular biomarkers in biological fluids and the identification of clinical or 
functional signs, both possibly anticipating motor symptoms. Imaging biomarkers targeting 
the premotor period are critical to elucidate both the onset and progression of premotor PD. 
Widespread data have demonstrated that functional imaging can detect PD subjects at the 
motor symptom threshold. Novel strategies combining functional imaging of the integrity of 
the dopaminergic neurotransmission (e.g., scanning of the DAT using a suitable tracer) with 
known genetic mutations for PD or early clinical signs and PD-associated symptoms, such as 






identify individuals at risk for PD before motor symptoms become manifest. Early studies 
also have used imaging techniques targeting norepinephrine, serotonin, cholinergic, or other 
neuronal systems to focus on early cardiac, cognitive, and behavioral symptoms. Imaging of 
nondopaminergic targets such as inflammation or α-synuclein deposition may provide further 
insight into the etiology of PD. Given the multiple genetic etiologies for PD already 
identified, the marked variability in the loss of dopaminergic markers measured by imaging at 
motor symptom onset, and the clear heterogeneity of clinical symptoms at PD onset, it is 
certain that many imaging biomarkers with a focus ranging from clinical symptoms to PD 
pathobiology to molecular genetic mechanisms, will be necessary to fully map PD risk 
(Marek and Jennings., 2009). 
 
1.8.1 Rationale for peripheral PD biomarkers 
Several evidences sustain the rationale to search for peripheral biomarkers of PD as early 
reporters of central neurodegeneration. First, up-regulation and/or genetic/post-translational 
modifications of α-synuclein and PD-related proteins should be appreciable even at the 
peripheral level, either in plasma, blood cells, or cerebrospinal fluid (CSF). Moreover, the 
immune system may sensibly reflect specific mechanisms of PD pathogenesis occurring at the 
central level. In particular, peripheral blood lymphocytes (PBLs) share with SNpc cells all the 
molecular machinery that makes functional a dopaminergic cell and may therefore represent 
sensitive reporters of PD pathogenesis (Fasano et al., 2008b).  
Altered α-synuclein metabolism in the CNS may be reflected in peripheral tissues. α-
synuclein has been found in body fluids including CSF and plasma. Although α-synuclein 
lacks an endoplasmic reticulum targeting signal sequence and is considered to be exclusively 
a cytoplasmic protein, recent findings support the hypothesis of physiological secretion and 
consequently the possibility to detect it in plasma or other body fluids (see Fasano et al., 
2008b). Further support to the systemic extension of PD comes from the pathogenetic 
hypothesis of Braak and coworkers (Braak et al., 2004) (see Paragraph 1.2 and 1.4). Motor 
symptoms become appreciable only at Braak‟s stage 3, i.e., when α-synuclein starts to 
assemble into the very first LB in SNpc neurons. Characteristic aggregates of α-synuclein 
have been found not only in the CNS, but also in the enteric nervous system, that is connected 
to the CNS via the vagal nerve (Braak et al., 2004). Although the precise topographic 
sequence has not yet been established, there are increasing evidences of peripheral autonomic 






diagnosis of PD and dementia with LB has been described (Kaufmann et al., 2004). While 
enriched in neurons, α-synuclein was also detected in peripheral cells such as skin, platelets, 
vascular cells, and PBLs (Fasano et al., 2008b). As a word of caution, it should be taken into 
account that the symptomatic therapy administered to PD patients may dramatically induce 
oxidative modifications of proteins and metabolites at the peripheral level. Therefore, 
biomarker discovery and validation processes always need to consider dependence of 
observed modifications from the dose of medications being administered (Fasano et al., 
2008b).  
 
1.8.2 Potential source for peripheral biomarkers of PD: Peripheral 
blood lymphocytes 
PBLs are easy to obtain from patients with little discomfort and may represent 
sensitive cellular sensors to be used for the evaluation of gene expression modification in 
physiological and pathological conditions, providing a unique and easily available biological 
model for integrated studies of gene expression in humans (Borro et al., 2007). Several 
evidences link PBLs to PD, sustaining the rationale for their use as a suitable pool of 
biomarkers. First, genetic traits may lead to changes in protein expression that bring to 
neurodegeneration in CNS and to some other specific functional alteration in PBLs. 
Moreover, PBLs may report on the activation of an immune response at the central level, 
either a primary event leading to cell death, or a secondary response to neuronal injury. 
Indeed, the hypothesis of a neuroimmune component of PD was also taken into account. 
Eventually, PBLs are circulating dopaminergic cells, therefore they could highlight alterations 
of genetic, environmental, or any other origin that become evident specifically in 
dopaminergic cells because of their marked oxidative challenge (Fasano et al., 2008b). 
The dogma of the immune privilege of the CNS has been challenged, based on the following 
observations: 1) the immune system patrols the CNS through continuous migration of 
leukocytes (Ransohoff et al., 2003); 2) the adaptive immune system affects cognitive 
performance and behavior (Kipnis et al., 2004); 3) the immune system, through T 
lymphocytes-sustained autoimmune mechanisms, may promote neuroprotective responses 
(see Cohen and Schwartz., 1999; Schwartz., 2000; Schwartz,.2001). Immune cells (PBLs, in 
particular) may mirror a systemic “trait”, possibly of genetic origin. Immune mechanisms 






(Fiszer, 2001), as well as by the demonstration of chronic neuroinflammatory processes in the 
brain of PD patients (McGeer and McGeer, 2004). This observation, coupled with the need 
for reliable and possibly manageable bio-markers of the disease, has prompted extensive 
investigation outside the CNS, particularly in peripheral blood cells, which have been shown 
to exhibit some of the changes observed at the nigral level – e.g., decreased complex I activity 
or increased oxidative stress (Blandini et al., 2003; Blandini et al., 2006; Martignoni et al., 
1999; Migliore et al., 2002). 




 T regulatory (Treg) cells seem to play a key role in 
autoimmune neuroprotection, and the neurotransmitter dopamine represents, at present, one of 









 T cells and a significantly increased ratio 
of IFN-gamma-producing to IL-4-producing T cells were observed in PD patients (Baba et 
al., 2005). 
Mutations in the parkin gene (PARK2) render PBLs more susceptible to dopamine- and iron-
mediated apoptosis (Jimenez Del Rio et al., 2004). PBLs show altered alpha-synuclein 
expression in PD patients, and alpha-synuclein appears to induce apoptosis in PBLs by 
enhanced expression of glucocorticoid receptor, caspase activation (caspase-8, caspase-9), 
CD95 up-regulation, and reactive oxygen species production (Kim et al., 2004). Oxidative-
stress-induced apoptosis has been reported in PBLs of two patients carrying the A53T alpha-
synuclein mutation (Battisti et al., 2008). The expression of transcription factor Nurr-1, which 
is critical in the development and maintenance of the dopaminergic system in the CNS, is 
reduced both in PD midbrains and in PBLs of parkinsonian patients (Jankovic et al., 2005).  
The functions of T cells are regulated not only by cytokines, but also by neurotransmitters, 
with a peculiar role exerted by dopamine (Pacheco et al., 2009). T lymphocytes express the 
same dopamine receptors expressed by neurons (D1 to D5), although the effect of dopamine 
stimulation on the same receptor may be different in different cells  (Pacheco et al., 2009). T 
cells are capable of synthesizing and/or capturing dopamine. PBLs, unlike monocytes, express 
tyrosine hydroxylase and store catecholamines into vesicles that are released through a 
synaptic-like mechanism (Cosentino et al., 2003; Cosentino et al., 2007; Marino et al., 1999). 
T cells possess transporters like DAT and VMAT, therefore they can internalize dopamine 
into specific vesicular storages similar to that impaired in PD pathogenesis (Cosentino et al., 






A marked alteration in calcium homeostasis has been reported in PBLs of PD patients 
showing levodopa-induced dyskinesias with respect to patients under levodopa treatment that 





 T cells, but not B cells, has been reported in SN specimens from PD patients and in 
a MPTP mouse model of PD, further supporting the functional link between 
neurodegeneration and immune system (Brochard et al., 2009). 
Indeed, modifications of dopaminergic receptor expression has been described in PBLs from 
PD patients (Barbanti et al., 1999; Nagai et al., 1996). Dopamine D1-like and D2-like 
receptors on PBLs in 50 de novo PD patients, in 36 neurological control subjects, and in 26 
healthy control subjects were assayed by radioligand binding assay techniques, showing a 
greater density of dopamine D1-like and D2-like receptors on PBLs in de novo PD patients 
than in either healthy control subjects or patients affected by different neurological diseases. 
Interestingly, treatment with L-DOPA or bromocriptine induced a down-regulation of both 
receptors to values comparable to those of control subjects (Barbanti et al., 1999). This up-
regulation, followed by a normalization after therapy, closely resembles the changes in the 
expression of putaminal D2-like receptors early demonstrated by PET studies in untreated PD 
patients (Antonini et al., 1994) and may suggest the existence of an adaptive response of 
peripheral receptors to the central dopaminergic deficit. These changes in the expression of 
dopamine D1-like and D2-like receptors on PBLs are therefore closely associated with PD 
and seem to represent a specific trait of such patients (Barbanti et al., 1999).  
In addition to the reported changes in DA receptor populations, DA transporters also appear 
to change significantly in PD. A recent study reported that measurement of DAT expression 
in PBLs allows to discriminate, possibly in the early clinical stages, PD patients from those 
affected by essential tremor, a neurological disorder characterized by postural and intentional 
tremor with slight signs of rigidity, that is not accompanied by central dopaminergic damage 
(Pellicano et al., 2007). DAT immunoreactivity was measured by densitometric analysis in 
PBLs from de novo PD or essential tremor patients with respect to healthy subjects, showing 
a reduction in PD that parallels that reported at the striatal level by SPECT (Benamer et al., 
2000). Therefore, the pathophysiological mechanisms underlying PD progression could 
directly or indirectly modify the expression of DAT at peripheral level (Pellicano et al., 
2007). The observation is in agreement with a previous report that showed a reduction of 
dopamine transporter immunoreactivity in PBLs in the early clinical stages of the disease 






In another study proteomics was used to search differentially expressed proteins in PBLs from 
sporadic PD patients in order to identify peripheral candidate biomarkers of substantia nigra 
degeneration using two-dimensional electrophoresis and mass spectrometry protein 
identification (Fasano et al., 2008b; Mila et al., 2009). To evaluate whether the 
pharmacological therapy could specifically affect the expression of responsive proteins, 
proteome maps from PD patients under dopaminergic drug treatment were matched with 
those from controls and from patients under deep brain stimulation of the subthalamic nucleus  
whose administered l-DOPA dose was significantly reduced. Three proteins were up-
regulated in PD patients and were respectively identified as cofilin 1, actin, and mitochondrial 
ATP synthase beta subunit, whereas in PD patients tropomyosin and gamma-fibrinogen were 
down-regulated. None of the selected spot volumes correlated with the administered l-DOPA 
dose. A linear combination of these spots was found that correctly classifies 7 out of 8 control 
subjects and 13 out of 13 PD patients selected in the study. Moreover, the level of a 
fibrinogen fragment linearly decreased with the years after onset, i.e., with the disease 
progression, regardless of the l-DOPA dosage (Mila et al., 2009).  
For all the reasons listed above, it is realistic that biochemical alterations at the SNpc level 
caused by genetic defects may also have a counterpart at the PBLs level (Fasano et al., 
2008b). In other words, mutations that lead to specific damage of dopaminergic neurons may 





2. AIM OF THE PROJECT





The emerging field of neuroproteomics promises to provide powerful strategies to further 
characterize neuronal dysfunction and cell loss associated with neurodegenerative diseases. 
Moreover, it could be a valuable tool for the biomarkers discovery phase. These potentialities 
are due to the fact that proteomics is an unbiased approach. 
The common threads of the two projects developed in this thesis are the technique used and 
the main subject, Parkinson‟s disease. 
In particular, two cell models are exploited: 
- SH-SY5Y neuroblastoma cell line, to investigate biochemical pathways altered by 
dopamine toxicity and α-synuclein overexpression. Altered dopamine homeostasis is a 
thoroughly accepted mechanism in the pathogenesis of Parkinson‟s disease, and α-
synuclein overexpression and impaired disposal contribute to this mechanism. 
Through this cell model we want to characterize from a molecular point of view 
pathogenetic mechanisms at the basis of neuronal cell death in PD. 
- Jurkat T-cell leukemia cell line, to understand proteome perturbations in peripheral 
dopaminergic cells, i.e., T-cells, after a non-oxidative, saturating dopamine stimulus. 
This investigation aims at substantiating the use of T-cells as an appropriate source of 
peripheral biomarkers and of Jurkat cells as a cell culture model to investigate 
dopamine-activated biochemical processes in T-cells. Eventually, the set of proteins 
whose level is modified by dopamine in Jurkat cells might represent by itself a 
reporter of dopaminergic functionality at the peripheral level, for instance in T-cells of 






3. MATERIALS AND METHODS





3.1 A SH-SY5Y MODEL TO INVESTIGATE PD PATHOGENETIC 
MECHANISMS 
3.1.1 Cell cultures and transfection 
 
Human neuroblastoma SH-SY5Y cells were cultured in 5% CO2 humidified atmosphere at 37 
°C in high-glucose Dulbecco‟s modified Eagle‟s medium (DMEM) with 10% fetal bovine 
serum (FBS), 100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM L-glutamine.  
The complete wild-type -synuclein coding sequence (aminoacids 1-140) was subcloned into 
the mammalian expression vector pcDNA3.1 (Invitrogen  Ltd, Paisley, UK) yielding plasmid 
pcDNA-Syn (Colapinto et al., 2006). SH-SY5Y cells were transfected with pcDNA-Syn by 
using Lipofectamine 2000 (Invitrogen). Briefly, cells were grown to 80% confluence in 24-
well plates for 24 h in complete growth medium without antibiotics and then exposed to a 
mixture of 2 l/well lipofectamine and 0.8 g/well pcDNA-Syn. Transfected cells were 
selected with 500 g/ml geneticin (Life Technologies, Paisley, UK) added to cell culture 48 h 
after transfection. -Synuclein-expressing cells (-syn) were further expanded in the presence 
of 200 g/ml  geneticin. Cells transfected with the pcDNA-β-gal plasmid, containing the β-
galactosidase complete sequence, were used as control (β-gal). Intentionally, cell lines were 
not cloned. This avoided working with only a few clones but, instead, resulted in an ensemble 
average of different clones. 
 
3.1.2 Cell viability 
 
The dopamine effect on cell viability was assessed by the MTT assay using the Celltiter 96 
non-radioactive cell proliferation assay (Promega, Madison, WI, USA), according to the 
manufacturer‟s instructions. Briefly, 4.0×10
4
 cells/well were seeded onto 96-well plates, 
grown for 24 h and exposed for further 24 h to different dopamine concentrations (0.125-1.00 
mM) in the presence of 700 U/ml catalase, in order to eliminate aspecific effects due to H2O2 
arising from dopamine auto-oxidation (Blum et al., 2000). At the end of the treatment, cells 
were washed twice with Phosphate Buffer Saline (PBS) to eliminate aspecific reduction of 
tetrazolium by dopamine and then incubated with the dye solution at 37 °C for 4 h; formazan 
crystals, formed by mitochondrial reducing activity, were dissolved in Solubilization/Stop 
Solution and the absorbance was read at 570 nm, using a Universal Microplate reader Model 





550 (Bio-Rad, Hercules, CA, USA).  Cell viability was calculated as follows: Abs570 
dopamine treated cells/ Abs570 control cells. All experiments were run in triplicate. 
 
3.1.3 2-DE electrophoresis and statistical analysis 
 
α-Syn and β-gal cells treated or not with 0.25 mM dopamine in the presence of catalase (700 
U/ml) for 24 h were collected by centrifugation, lysed with 200 μl lysis solution (7 M urea, 2 
M thiourea, 4% w/v CHAPS, 0.5 l protease inhibitor mix; Sigma-Aldrich, Milan, Italy) and 
centrifuged (13000 g, 30 min, 10 °C). Proteins were collected in the supernatant and their 
concentration was determined using the Bio-Rad Protein Assay (Bio-Rad). 
  2-DE was performed according to Görg (Görg et al., 2000), with minor modifications. 
Samples (about 200 g) were diluted to 250 l with a buffer containing 7 M urea, 2 M 
thiourea, 4% CHAPS, 0.5% IPG buffer 3-10, 2 mM tributylphosphine and traces of 
bromophenol blue, and loaded on 13 cm IPG DryStrips with a non-linear 3-10 pH gradient by 
in-gel rehydration (1 h at 0 V, 10 h at 50 V). IEF was performed at 20°C on IPGphor (GE 
Healthcare, Little Chalfont, UK) according to the following schedule: 2 h at 200 V, 2 h linear 
gradient to 2000 V, 2 h at 2000 V, 1 h of linear gradient to 5000 V, 2 h at 5000 V, 2 h linear 
gradient to 8000 V and 2 h and 30 min at 8000 V. IPG strips were then equilibrated for 2 × 30 
min in 50 mM Tris-HCl pH 8.8, 6 M urea, 30% glycerol, 2% SDS and traces of bromophenol 
blue containing 1% DTT for the first equilibration step and 2.5% iodoacetamide for the 
second one. SDS-PAGE was performed using 13% 1.5 mm thick separating polyacrylamide 
gels without stacking gel, using Hoefer SE 600 system (GE Healthcare). The second 
dimension was carried out at 45 mA/gel at 18°C. Molecular weight marker proteins (11-170 
kDa from Fermentas, Burlington, Canada) were used for calibration. 
 Gels were stained according to MS-compatible silver staining method (Gromova et al., 
2006), scanned with an Epson Perfection V750 Pro transmission scanner (Epson, Nagano, 
Japan) and analyzed with ImageMaster 2D Platinum V5.0 software package (GE Healthcare). 
Spots were detected automatically by the software and manually refined hereafter; gels were 
then matched and the resulting clusters of spots confirmed manually. Unmatched spots among 
the experimental groups were considered as qualitative differences. Synthetic images 
(“average gels”) comprised of spots present in more than 80% of the gels were built for each 
group and then compared; spots have been quantified on the basis of their relative volume 
(spot volume normalized to the sum of the volumes of all the representative spots) and those 





that consistently and significantly varied among the different populations were identified by 
ANOVA analysis with a threshold of p≤0.05 using the StatistiXL software 
(http://www.statistixl.com). 
 
3.1.4 LC-MS-MS analysis for protein identification 
 
Silver-stained spots were manually excised and destained (1 × 10 min 50 µl K3[Fe(CN)6] 30 
mM and Na2S2O3 100 mM, 6 × 10 min 100 µl deionized water, 1 × 20 min 100 µl NH4HCO3 
200 mM, 1 × 20 min 100 µl deionized water), dehydrated with acetonitrile (1 × 40 min 100 
µl) and then dried at 37°C by vacuum centrifugation. The gel pieces were then swollen in 10 
µl digestion buffer containing 50 mM NH4HCO3 and 12.5 ng/µl modified porcine trypsin 
(sequencing grade, Promega). After 10 min 30 µl of 50 mM NH4HCO3 were added to the gel 
pieces and digestion allowed to proceed at 37° C overnight. The supernatants were collected 
and peptides were extracted in an ultrasonic bath for 10 min (twice 100 µl 50 % acetonitrile, 
50 % H2O, 1% formic acid v/v; once 50 µl acetonitrile). All the supernatants were collected in 
the same tube, dried by vacuum centrifugation and dissolved in 20 µl 2% acetonitrile, 0.1 % 
formic acid in water. 
 Peptide mixtures were separated by using a nanoflow-HPLC system (Agilent 
Technologies series 1200, Santa Clara, CA, USA). A sample volume of 10 µl was loaded onto 
a 2 cm fused silica pre-column (75 µm I.D.; 375 µm O.D.) at a flow rate of 2 µl/min. Peptides 
were eluted at a flow rate of 200 nl/min with a linear gradient from Solution A (2% 
acetonitrile; 0.1% formic acid) to 50% of Solution B (98% acetonitrile; 0.1% formic acid) in 
40 minutes over the pre-column in-line with a homemade 15 cm resolving column (75 µm 
I.D.; 375 µm O.D.; Zorbax 300-SB C18, Agilent Technologies). Peptides were eluted directly 
into a Esquire 6000 Ion Trap mass spectrometer (Bruker-Daltonik, Bremen, Germany). 
Capillary voltage was 1.5-2 kV and a dry gas flow rate of 10 l/min was used with a 
temperature of 230 °C. The scan range used was from 300 to 1800 m/z. The tandem mass 
spectra were annotated and peak list files were generated, commonly referred to as .MGF 
files, by running DataAnalysis version 3.2 (Bruker-Daltonik) using default parameters. 
Protein identification was manually performed by searching the National Center for 
Biotechnology Information non-redundant database (NCBInr 20081021; 709593 sequences 
actually searched) using the Mascot MS/MS Ion Search program (version 27 Oct 2008; 
http://www.matrixscience.com). The following parameters were set: enzyme trypsin, 





complete carbamidomethylation of cysteines and partial oxidation of methionines, peptide 
Mass Tolerance ± 0.9 Da, Fragment Mass Tolerance ± 0.9 Da, missed cleavages 2, species 
restriction to human. All identified proteins have a Mascot score greater than 69, 
corresponding to a statistically significant (p < 0.05) confident identification. Among the 
positive matches, only protein identifications based on at least two different non-overlapping 
peptide sequences of more than 6 amino acids and with a mass tolerance <0.9 Da were 
accepted.  
 
3.1.5 Bioinformatics enrichment and network clustering 
 
Identified proteins were clustered in two groups. The first one corresponds to proteins that 
displayed significant changes in their levels following dopamine treatment. The second one 
groups together proteins that showed quantitative alterations in response to α-synuclein 
overexpression, or that differentially responded to dopamine exposure as a function of α-
synuclein overexpression. Lists were fed to PPI spider (http://mips.helmholtz-
muenchen.de/proj/ppispider/) in order to determine a statistically-significant interaction 
network as well as statistically-significant functional association to Gene Ontology (GO) 
classifications (Antonov et al., 2009).  
 
3.1.6 Apoptosis analysis 
 
The induction of apoptotic cell death was analyzed by flow cytometry with the Annexin V-
FITC apoptosis detection kit (BD, Becton-Dickinson, Franklin Lakes, NJ, USA). Briefly, 
cells treated or not with 0.250 mM dopamine in the presence of catalase (700 U/ml) for 24 h 
were resuspended (1×10
6
 cells/ml) in binding buffer; 1×10
5
 cells were incubated with 
Annexin V-FITC and propidium iodide for 15 min at room temperature (RT) in the dark. 
Samples properly diluted were analyzed with a FACSCalibur flow cytometer (BD) equipped 
with a 15-mW, 488-nm, air-cooled argon ion laser. At least 10,000 events were analyzed for 
each sample and data were processed using CellQuest software (BD). Fluorescent emission of 
propidium iodide and Annexin V-FITC were collected through a 575 and a 530/30 band-pass 
filter, respectively. The percentage of apoptotic cells in each sample was determined based on 





the fraction of Annexin V positive cells, whereas the percentage of necrotic cells was 
determined based on the fraction of propidium iodide positive cells. 
 
3.1.7 Transient transfection and luciferase gene reporter assay 
 
β-Gal and α-syn cells (60% confluent in six-well plates) were transfected with pNF-κB-Luc 
plasmid (Stratagene, Santa Clara, CA, USA) (150 ng/well) and phRL-CMV, containing 
Renilla luciferase cDNA (5 ng/well), using Lipofectamine and OptiMEM medium 
(Invitrogen, Carlsbad, CA). In pNF-κB-Luc the expression of the firefly luciferase is 
controlled by a synthetic promoter containing five NF-κB binding sites. After 7 hours 
incubation, the transfection mixture was replaced with complete DMEM containing or not 
0.25 mM dopamine, in the presence of 700 U/ml catalase. Cells were harvested after 2 and 24 
hours, lysed and the cell lysates were tested for luciferase activities by using the Dual-
Luciferase reporter assay system (Promega), according to manufacturer‟s instruction. 
Experiments were performed in duplicate and repeated three times with nearly identical 
results in order to gain statistical significance (verified by Student's t-test). NF-κB-dependent 
luciferase activity was normalized to the Renilla luciferase activity present in each sample.  
 
3.1.8 Western blotting of α-synuclein, HSP70 and 14-3-3 
 
Expression of -synuclein, HSP70 and 14-3-3 was determined by Western blotting. β-Gal 
and α-syn cells treated or not with 0.250 mM dopamine in the presence of catalase (700 U/ml) 
for 24 h were lysed in RIPA buffer (25 mM Tris-HCl pH 7.4, 0.15 M NaCl, 0.1% SDS, 1% 
Triton X-100, 1% sodium deoxycholate). Proteins (80 μg) were resolved by SDS-PAGE on a 
16% polyacrylamide gel and then transferred to a PVDF membrane (Roth, Karlsruhe, 
Germany) at 25 V for 2h. The membrane was incubated with different primary antibodies (see 
Table 2) diluted in 5% nonfat dry milk in TBS-T (10 mM Tris HCl pH 8, 150 mM NaCl, 
0.05% Tween 20) for 1.5 h at RT. Protein bands were visualized using a peroxidase-
conjugated IgG secondary antibody (see Table 3) and the ECL plus western blotting detection 
system (Millipore, Billerica, MA, USA). Relative levels of -synuclein, HSP70 and 14-3-3 
were calculated by densitometric analysis (ImageJ software; http://rsb.info.nih.gov/ij) and 
normalized to β-actin. 





Table 2: List of primary antibodies, the dilution used and the supplier. 
 
 Antibody Dilution Supplier 
Mouse anti-α-synuclein 1:1000 BD Transduction Laboratories, Franklin Lakes, USA 
Mouse anti-HSP70 1:1000 Zymed Laboratories, San Francisco, USA 
Rabbit anti-14-3-3 1:1000 Zymed Laboratories, San Francisco, USA 
Mouse anti-β-actin 1:3000 GeneTex, Irvine, USA 
 
 
Table 3: List of HRP conjugated secondary antibodies, the dilution used and the supplier. 
 
Antibody Dilution Supplier 
Anti rabbit polyclonal IgG-HRP conjugated 1:1000 Millipore, Tamekula, CA, USA 
Anti mouse polyclonal IgG-HRP conjugated 1:3000 GeneTex, Irvine, USA 
 
 
3.1.9 Cell cycle analysis 
 
The effect on cell cycle distribution by 24 h exposure to 0.25 mM dopamine was analyzed by 
flow cytometry. α-Syn and β-gal cells treated or not with 0.25 mM dopamine in the presence 
of catalase (700 U/ml) were detached by trypsinization, washed in phosphate-buffered saline 
(PBS) and fixed in ice-cold 70% ethanol for 20 min at -20°C. After a further wash in PBS, 
DNA was stained with 50 μg/ml propidium iodide (PI) in PBS in the presence of RNAse A 
(30 U/ml) at 37°C for 30 minutes. 
All samples were analyzed with a FACSCalibur flow cytometer (BD) equipped with a 15-
mW, 488-nm, air-cooled argon ion laser. At least 10,000 events were analyzed for each 
sample and all data were processed using CellQuest software (BD). Fluorescent emission of 
PI was collected through a 575 band-pass filter, acquired in linear mode for cell cycle 
analysis.  
Through the flow cytometry analysis it is possible to distinguish among cells with 2n DNA 
content (G1 phase), cells with 4n DNA content (G2/M phase) and cells with an intermediate 
DNA content (S phase). 
 





3.1.10 Western blotting of Voltage Dependent Anion Channels 
(VDACs) 
MONODIMENSIONAL WESTERN BLOTTING (TIME COURSE) 
SH-SY5Y wild type cells were treated or not with 0.25 mM dopamine in the presence of 
catalase (700 U/ml) for 4, 7, 12 and 24 h. Cells were then harvested and proteins extracted as 
described in Paragraph 3.1.8. Thirty micrograms of total proteins were resolved by SDS-
PAGE on a 13% polyacrylamide gel and then transferred to a PVDF membrane (see 
paragraph 3.1.8).  
The membrane was incubated with anti VDACs, anti-grp75 or anti-HSP60 primary antibodies 
(see Table 4) diluted in 5% nonfat dry milk in TBS-T overnight at 4°C. Protein bands were 
visualized using a peroxidase-conjugated IgG secondary antibody (see Table 5) and the ECL 
plus western blotting detection system. Relative levels of VDAC1, VDAC2 and VDAC3 were 
calculated by densitometric analysis (ImageJ software) and normalized to β-actin. 
 
Table 4: List of primary antibodies, the dilution used and the supplier. 
 
Antibody Dilution Supplier 
Rabbit anti VDAC1 1:1800 Abcam, Cambridge, UK 
Goat anti VDAC2 1:2000 Abcam, Cambridge, UK 
Chicken anti VDAC3 1:500 Abcam, Cambridge, UK 
Rabbit anti-grp75 1:10000 Santa Cruz Biotech., Santa Cruz, USA 
Goat anti-HSP60 1:1000 Santa Cruz Biotech., Santa Cruz, USA 
 





Table 5: List of HRP conjugated secondary antibodies, the dilution used and the supplier 
 
Antibody Dilution Supplier 
Anti goat polyclonal IgG-HRP conjugated  1:3000 Millipore, Tamekula, CA, USA 
Anti rabbit polyclonal IgG-HRP conjugated 1:1000 Millipore, Tamekula, CA, USA 
Anti chicken polyclonal IgG-HRP conjugated 1:5000 Millipore, Tamekula, CA, USA 
 
VDAC2 TWO-DIMENSIONAL WESTERN BLOTTING  
SH-SY5Y wild type cells were treated or not with 0.250 mM dopamine in the presence of 700 
U/ml catalase for 4 or 7 h. Cells were lysed using UTC (see Paragraph 3.1.3). Sixty 
micrograms of total proteins were loaded onto 7 cm IPG DryStrip with a non-linear 7-11 pH 
gradient by in-gel rehydration (1 h at 0 V, 10 h at 25 V). IEF was performed at 20° C 
according to the following schedule: 0,5 h linear gradient to 300 V, 3 h at 300 V, 3,5 h of 
linear gradient to 3500 V, 3500 V to 20000 Vhrs. IPG strips were then equilibrated as 
described in Paragraph 3.1.3. SDS-PAGE, transfer of proteins on PVDF membrane and 
immunodetection were performed as detailed in Paragraph 3.1.10. 
 
3.1.11 Tetramethylrhodamine methyl ester (TMRM) staining 
 
Inside a healthy, non-apoptotic cell, the lipophilic tetramethylrhodamine methyl ester 
(TMRM, Molecular Probes, Invitrogen Co.) dye, bearing a delocalized positive charge, enters 
the negatively charged mitochondrion where it accumulates in an inner-membrane potential-
dependent manner. When the mitochondria collapse in apoptotic or otherwise depolarized 
cells, the TMRM potentiometric dye no longer accumulates inside the mitochondria and 
becomes evenly distributed throughout the cytosol. When dispersed in this manner, overall 
cellular fluorescence levels decrease dramatically and this event can easily be visualized by 
fluorescence microscopy or quantitated by flow cytometry or fluorescence plate reader 
analysis techniques.  
4×10
5
 SH-SY5Y cells were seeded on 24 mm coverslip and grown for 24 hours. Afterwards, 
they were treated or not with 0.25 mM dopamine in the presence of 700 U/ml catalase for 24 
h. For measurement of the mitochondrial membrane potential (ΔΨm), cells were loaded with 
10 nM TMRM for 30 min at 37°C in KRB/Ca
2+
 solution and then placed in a thermostated 
chamber on the stage of a Zeiss Axiovert 200 inverted microscope equipped with a BD Carv-





II confocal head and a high sensitivity back-illuminated EM-CCD camera (Cascade 512b, 
Photometrics). Images were taken with a 63× 1.4 N.A. Plan-Apochromat objective with 500 
ms exposure time. TMRM intensity was quantified by measuring the average pixel intensity 
of the whole cell on background-corrected images after thresholding with the Metamorph 7.5 
software.  
 
3.1.12 Measurement of Ca2+ flux to mitochondria using Aequorin  
 
Aequorin is a 21 kDa protein isolated from Aequorea sp. Jellyfish, which emits blue light in 
the presence of calcium ions (Shimomura, 1988). In its active form the photoprotein includes 
an apoprotein and a covalently bound prosthetic group, coelenterazine. When calcium ions 
bind to the three high affinity EF hand sites, coelenterazine is oxidized to coelenteramide, 
with a concomitant release of carbon dioxide and emission of light. Reconstitution of an 
active aequorin (expressed recombinantly) can be obtained also in living cells by simple 
addition of coelenterazine to the medium. Coelenterazine is highly hydrophobic and has been 
shown to permeate cell membranes of various cell types.  
Recombinant aequorin can be targeted to the mitochondria (mtAEQ) thanks to a targeting 
presequence of subunit VIII of human cytochrome c oxidase fused to the aequorin cDNA 
(Porcelli et al., 2001). Additionally, the aequorin D119A mutant is used, which has the high 
affinity calcium binding site inactivated so that calcium concentrations in the range of 10 to 
100 μM can be measured (Kendall et al., 1992). 
 
CELL PREPARATION, CALCIUM-PHOSPHATE TRANSFECTION PROCEDURE AND 
RECONSTITUTION OF FUNCTIONAL AEQUORIN 
 
One day before the transfection step, SH-SY5Y cells were plated on a 13 mm round coverslip 
at 30-50% confluence. Just before the transfection procedure, cells were washed with 1 ml of 
fresh medium. 
For 1 coverslip, 5 µl of 2.5 M CaCl2 were added to 4 µg of DNA dissolved in 45 µl of Tris-
EDTA (TE= 10mM Trizma-base, 1mM EDTA, pH 8). The solution was mixed by vortexing 
with 50 µl of HEPES Buffered Solution (HBS= 280 mM NaCl, 50 mM Hepes, 1.5 mM 
Na2HPO4, , pH 7.12) and incubated for 30 min at RT. The solution was then added directly to 





the cell monolayer. After 24 h, cells were washed with PBS (2 or 3 times until the excess 
precipitate is completely removed).  
Once expressed, the recombinant aequorin must be reconstituted into the functional 
chemiluminescent protein. This is accomplished by incubating cells with synthetic 
coelenterazine (5 µM) at 37°C in fresh DMEM medium supplemented with 1% FCS for 1 h.  
Cells were then treated or not with 0.25 mM dopamine in the presence of 700 U/ml catalase 
for 4 or 24 h. 
 
LUMINESCENCE DETECTION AND Ca2+ MEASUREMENT 
 
The aequorin detection system is based on the use of a low noise photomultiplier placed in 
close proximity (2-3 mm) of aequorin expressing cells. The cell chamber, which is on the top 
of a hollow cylinder, is adapted to fit a 13-mm diameter coverslip. The volume of the 
perfusing chamber is kept to a minimum (about 200 µl). The chamber is sealed on the top 
with a coverslip, held in place with a thin layer of silicone. Cells are continuously perfused 
via a peristaltic pump with medium thermostated via a water jacket at 37°C. The 
photomultiplier (EMI 9789 with amplifier-discriminator) is kept in a dark box. The output of 
the amplifier-discriminator is captured by an EMIC600 photon-counting board in an IBM 
compatible microcomputer and stored for further analysis. 
The coverslip with transfected cells is transferred to the luminometer chamber and perfused 
with KRB saline solution in the presence of 1 mM CaCl2 and 1g/l glucose to remove the 
excess of coelenterazine. Bradykinin (100 nM) was added to the perfusing medium.  
Luminescence values are reported as a function of time following calcium release induced by 
bradykinin. Statistical significance was verified by Student's t test. 
 
3.1.13 Two-dimensional Western blotting of DJ-1 
 
For two-dimensional electrophoresis, 3.5×10
6
 SH-SY5Y cells were seeded in 3% FBS and 
treated with 0.1 mM dopamine in the presence of 700 U/ml catalase in the medium to remove 
exogenous H2O2 (Blum et al., 2000). Cells treated for 15 min with 1.0 mM H2O2 were used as 
positive control of a generic oxidative stress. After 24 h incubation cells were scraped, 
collected by centrifugation and lysed with 200 μl UTC containing protease inhibitors, and 
sonicated for 15 seconds. After 90 min DNase I and RNase A (Sigma-Aldrich) were added, 





and after further 10 min specimens were centrifuged (13000×g, 30 min, 10°C). The protein 
concentration was estimated by Bradford assay (Bio-Rad).  
2-DE was performed as described in Paragraph 3.1.3. Gels were transferred to PVDF 
membranes at 25 V for 2 h. Membranes were saturated in 5% non-fat milk in TBS-T and 
incubated with goat anti-DJ-1 polyclonal antibody (Abcam), 1:1000 dilution in 5% milk-TBS-
T for 1.5 h at room temperature or with mouse anti-β-actin monoclonal antibody (see Table 
2). Membranes were then washed with TBS-T and incubated with peroxidase-conjugated 
secondary antibodies (see Tables 3 and 5) for chemiluminescence detection (Pierce, Rockford, 
IL, USA). Photographic films were scanned with a Epson Perfection V750 Pro transmission 
scanner (Epson) and images were analyzed using ImageJ (http://rsb.info.nih.gov/ij/). 
Statistical significance was verified by Student's t test.  
  
3.1.14 2-DE gel alignment and “metagel” production 
 
2-DE images in the literature (Bandopadhyay et al., 2004; Canet-Avilés et al., 2004; 
Colapinto et al., 2006; Motani et al., 2008) showing DJ-1 spots have been rescaled and 
registered on the reference pI/MW grid, background-subtracted, segmented for the spots and 
binarized (Natale et al., 2010). The 6 binarized images were used to get a “metagel”, i.e., an 
average intensity projection image, wherein each pixel stores the average intensity over the 6 
original images at corresponding pixel location. The color scale of this metagel accounts for 
the occurrence frequency of each spot in the considered experiments, with less frequent spot 
positions in blue and more frequent spot positions in white.





3.2 DOPAMINE RESPONSE OF DOPAMINERGIC CIRCULATING CELLS: 
THE JURKAT CELL MODEL  
 
3.2.1 Cell culture 
 
The Jurkat T-cell leukemia cell line was maintained at 37°C in a 5% CO2 humidified 
atmosphere in RPMI 1640, supplemented with 10% fetal bovine serum (FBS), 100 U/ml 
penicillin, 100 μg/ml streptomycin, and 2 mM L-glutamine. Stock flasks were transferred for 
culture twice weekly or as required to maintain optimal cell growth. All cell culture media 
and reagents were from PAA (Pashing, Austria). 
 
3.2.2 RNA extraction, retrotranscription and PCR 
 
RNA was extracted using NucleoSpin RNA II (Macherey-Nagel, Düren, Germany) following 
manufacturer‟s instructions and treated with rDNase in order to remove genomic DNA. Five
 
micrograms of RNA were reverse transcribed into first-strand cDNA
 
in a 20 µl final volume 
using the Maxima™ First Strand cDNA Synthesis Kit (Fermentas). PCR was performed by 
Real-Time PCR
 
(DNA Engine Opticon 2; MJ Research, Waltham, MA, USA) using a SYBR 
Green PCR mix (5Prime, Hamburg, Germany). The expression of D1 receptor (DRD1), D2 
receptor splicing variants 1 and 2 (DRD2_1 and DRD2_2), D3 receptor splicing variant a 
(DRD3_a), D4 receptor (DRD4), D5 receptor (DRD5), dopamine transporter (DAT), 
vesicular monoamine transporter 1 and 2 (VMAT1, VMAT2) and tyrosine hydroxylase (TH) 
was evaluated using primers reported in Table 6. Optimal PCR conditions were identified for 
each primer pair. Reactions were incubated at 95°C for 2 min, then 40 cycles of 95°C for 15 
sec, 62°C for 20 sec, 68°C for 20 sec.  As positive control, cDNA from the catecholaminergic 
human neuroblastoma SH-SY5Y cell line was used and amplified under the same conditions. 
The specificity of the amplified products was checked by the melting temperature curve 
analysis and the expected size of the fragments was further visualized in a 2% agarose gel 
stained with ethidium bromide. Results were confirmed by three independent replicates. 
Furthermore, PCR efficiency was determined using serial dilution of control templates 
obtained by the amplification of positive controls. The dilutions were used as templates for 
PCR reactions. C(t) values were plotted against the log10 number of template and the slope of 





the obtained line defines the reaction efficiency calculated as equal to 10
(-1/slope)
. All PCR 
reactions, thus, displayed similar and optimal efficiency for each primer specific amplification 
protocol. 
 
PRIMER DESIGN  
 
Primer design was performed by using Primer3 software (http://primer3.sourceforge.net/) and 
manually adjusted if needed. Primer pairs were designed to avoid the amplification of 
undesired sequences that share high identity degree and the amplification of common 
sequences among the splicing variants of the same transcript. Moreover, primers were 
designed to have comparable melting temperature and reaction efficiency. Primer specificity 
was tested by BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and experimentally by the 
positive control amplification. 





Table 6: Sequences of specific primers: F = forward primer; R = reverse primer. 
Gene Primer Sequence Amplicon size (bp) 
D1 F ATGGACGGGACTGGGCTGGT 
91 
D1 R GGAGCGTGGACAGGATGAGCA 
D2_1 F AGCCTCCACTCTCCGCCTG 
102 
D2_1 R CCACTAAAGGGCAACTGTACTCACC 
D2_2 F CGCCGGGCAGCCTCCTTTAG 
156 
D2_2 R CCATCGTCTCCTTCTACGTGCCC 
D3_a F GGCACTCCCCGAGGTTGCAG 
116 
D3_a R CGGAATTCCCTGAGTCCCACC 
D4 F GCCGACCTCCTCCTCGCTCT 
169 
D4 R CGAACCTGTCCACGCTGATGG 
D5 F TCTACCGCATCGCCCAGGTG 
189 
D5 R GCAGCCAGCAACACACGAAGA 
VMAT1 F GCTTTCTTCAACAGCCACGGTG 
170 
VMAT1 R CTGTGGTGGTGCCAATTGTGC 
VMAT2 F CCATTGCGGATGTGGCATTT 
166 
VMAT2 R TCTTCTTTGGCAGGTGGACTTCG 
DAT1 F AGCCTGCCTGGGTCCTTTCG 
106 
DAT1 R AGTGGCGGAGCGTGAACTGG 
TH F CGACCCTGACCTGGACTTGGA 
142 
TH R GGCAATCTCCTCGGCGGTGT 





3.2.3 2-DE electrophoresis and quantitative analysis  
 
Jurkat cells treated or not with 50 µM dopamine in the presence of 140 U/ml catalase (Blum 
et al., 2000) for 24 h were collected by centrifugation, lysed with 200 μl UTC + 0.5 l 
protease inhibitor mix and centrifuged (13000 g, 30 min, 10 °C). Proteins were collected in 
the supernatant and their concentration was determined using the Bio-Rad Protein Assay 
(Bio-Rad). 
2-DE was performed as described in Paragraph 3.1.3. SDS-PAGE was performed using 11% 
separating polyacrylamide gels. Gels were stained with Coomassie Brilliant Blue R-350, 
scanned with an Epson Perfection V750 Pro transmission scanner (Epson) and analyzed with 
ImageMaster 2D Platinum V5.0 software package (GE Healthcare). Spots that consistently 
and significantly varied between controls and dopamine-treated samples were identified by 
Student‟s t-test analysis with a threshold of p≤0.05. 
 
3.2.4 Protein identification by matrix-assisted laser desorption 
ionization time-of-flight (MALDI-TOF) mass spectrometry  
 
Protein spots were excised manually from the gel, washed with high-purity water and 
destained twice with 100 μl of 50 mM NH4HCO3/50% acetonitrile for 10 min. Spots were 
dehydrated with 100% acetonitrile and swollen at RT in 20 μl of 40 mM NH4HCO3/10% 
acetonitrile containing 25 ng/μl trypsin (Trypsin Gold, mass spectrometry grade; Promega). 
After 1 h, 50 μl of 40 mM NH4HCO3/10% acetonitrile were added and digestion proceeded 
overnight at 37°C. The generated peptides were extracted with 50% acetonitrile/5% 
trifluoroacetic acid (TFA; two steps, 20 min at RT each), dried by vacuum centrifugation, 
suspended in 0.1% TFA, passed through micro ZipTip C18 pipette tips (Milllipore) and eluted 
directly with the MS matrix solution (10 mg/ml α-cyano-4-hydroxycinnamic acid in 50% 
acetonitrile/1% TFA). Mass spectra of the tryptic peptides were obtained using a Voyager-DE 
MALDI-TOF mass spectrometer (Applied Biosystems, Foster City, CA, USA). Peptide mass 
fingerprinting database searching was performed using the mascot search engine 
(http://www.matrixscience.com) in the NCBInr/Swiss-Prot databases. Parameters were set to 
allow one missed cleavage per peptide, a mass tolerance of 0.5 Da and considering 





carbamido-methylation of cysteines as a fixed modification and oxidation of methionines as a 
variable modification.  
3.2.5 Bioinformatics enrichment and network clustering 
 
The list of identified proteins was fed to PPI spider (http://mips.helmholtz-
muenchen.de/proj/ppispider/) in order to determine a statistically-significant interaction 
network as well as statistically-significant functional association to Gene Ontology (GO) 
classifications (Antonov et al., 2009).  
 
3.2.6 Two-dimensional Western blotting of 14-3-3 and β-actin 
 
2-DE was performed as described in Paragraph 3.1.3. Western blotting conditions for 14-3-3 
and β-actin detection are detailed in Paragraph 3.1.8. Images were acquired using two 
different exposure times, in order to discriminate differences in both low- and high-abundance 
species. By saturating the main component, we were able to observe minor spots. By lowering 
the exposure time, on the other hand, minor spots disappear and the most abundant isoforms 
appeared as resolved spots. Photographic films were scanned with a Epson Perfection V750 















4.1 A SH-SY5Y MODEL TO INVESTIGATE PD PATHOGENETIC 
MECHANISMS 
 
4.1.1. Dopamine toxicity in β-gal and α-syn SH-SY5Y cells 
 
To obtain a cellular model of α-synuclein overexpression, the human neuroblastoma cell line 
SH-SY5Y was stably transfected with the plasmid containing human α-synuclein cDNA (α-
syn) and, as a control, SH-SY5Y cells stably transfected with the plasmid containing β-
galactosidase cDNA were used (-gal) (see Materials and Methods, Paragraph 3.1.1). 
The optimal dopamine concentration to be used in this study was determined by MTT assay. 
The dopamine effect on cell viability was assessed exposing both β-gal and α-syn SH-SY5Y 
cells to different dopamine concentrations (0.125, 0.25, 0.5, 1 mM) for 24 h (see Figure 6). 
Dopamine treatment was always performed in combination with catalase, in order to 
eliminate extracellular hydrogen peroxide, formed by dopamine oxidation (Blum et al., 2000). 
Results are reported as the mean percentage of viable cells, obtained by the Abs570 ratio of 
dopamine treated cells (β-gal and α-syn cells treated with 700 U/ml catalase + different 
dopamine concentrations) and controls (β-gal and α-syn cells treated with 700 U/ml catalase 
only) of three independent experiments.  
 
 
Figure 6: Dose dependent dopamine effect on cell viability measured by MTT 
assay. Continuous line: β-gal cells. Dashed line α-syn cells. All experiments were 
performed in the presence of 700 U/ml catalase. Values are the means  SD of three 
independent experiments. For details and experimental conditions see Materials and 






Figure 6 shows that dopamine is toxic in the range 0.125-1 mM on both β-gal and α-syn cells. 
Incrising concentrations of dopamine reduced progressively cell viability. Moreover, α-syn 
cells were less resistant to higher dopamine concentrations (0.5 and 1 mM). 
Since the percentage of viable cells was still acceptable to conduct the proteomic analysis 
(70±5%) and the toxicity was almost identical for the two cell lines, the concentration chosen 
for all further experiments was 0.25 mM.  
 
4.1.2 Dopamine increases the expression of α-synuclein to a threshold  
 
Quantification of α-synuclein overexpression was performed by Western blot, revealing a 
significant 1.5-fold increase in α-synuclein expression in α-syn cells with respect to -gal 
cells (Figure 7).  
As dopamine upregulates α-synuclein expression (Gómez-Santos et al., 2003), α-synuclein 
level was measured in α-syn cells with respect to β-gal cells in the presence of catalase only 
(cat) or in the presence of catalase and 0.25 mM dopamine (DA) for 24 h. Dopamine 
treatment significantly increased 1.5-fold the expression of α-synuclein in β-gal control cells 
(SH-SY5Y β-gal DA), but not in α-syn cells that already overexpress it as a consequence of 




Figure 7: Relative expression of α-
synuclein in β-gal and α-syn cells in 
response to dopamine treatment. Results 
are indicated as fold of induction relative to 
expression observed in β-gal cells treated 
with catalase (SH-SY5Y β-gal cat, set to 
1). Values (density of α-synuclein bands 
normalized to β-actin) are the mean  SE 
of three independent experiments. * p < 






4.1.3 Proteomics analysis reveals quantitative changes in 23 proteins 
 
Proteomic investigations were conducted on β-gal and α-syn cells treated or not with 
dopamine as described in Materials and Methods, Paragraph 3.1.3. Statistical analysis (by 
two-way ANOVA) of silver-stained gel images revealed 28 spots whose intensity was 
significantly different in at least one of the four groups considered here (Figure 8). 
Two groups of spots showing remarkable changes in the isoform pattern in the four conditions 
were easily assigned to glyceraldehyde-3-phosphate dehydrogenase and to mitochondrial 
ATP synthase alpha subunit by comparison with 2-DE maps available in the SWISS 2D-
PAGE database (http://www.expasy.org/swiss 2dpage). Additionally, 21 differentially 
expressed proteins were identified by LC-MS-MS (see Table 7 and Table 8).  
After dopamine treatment one spot completely disappeared (VDAC-2) and 10 proteins 
(pyruvate kinase, RPLP2, eIF5A, parathymosin, L7/L12, annexin A2, Annexin A5, aldolase 
A, fascin 1, and peroxyredoxin 1) displayed quantitative differences (see insets in Figure 8; 
black vs. white bars). Dopamine-responsive proteins are involved in protein synthesis, 
energetic metabolism, calcium-dependent phospholipid binding, cytoskeleton regulation, 
redox homeostasis and mitochondrial electrochemical balance.  
Regardless of treatment, overexpression of α-synuclein significantly affected the levels of 4 
proteins (stathmin 1, GSTπ, Ran 1 binding protein, C1q binding protein), related to cell 
signaling, apoptosis and cytoskeleton regulation (see insets in Figure 8; shaded vs. white 
bars).  
On the other hand, 6 proteins were regulated in a more complex way (see insets in Figure 8; 
4-bar histograms), i.e., α-synuclein overexpression modulated the dopamine effect (profilin 1, 
enolase 1, RuvB-like 1, CRMP4, lamin A/C, mitofilin). These proteins deal with regulation of 









Figure 8: A representative silver-stained 2-DE gel of proteins extracted from β-gal 
cat cells. Qualitative differences are indicated by squares (A: ATP synthase α; B: 
GAPDH; C: VDAC2), whereas circles indicate spots whose levels change 
significantly as indicated by insets. Values (fold of induction with respect to the 
reference condition) are the mean  SD of three different gels in 4-bars histograms 







Table 7: Identification of differentially expressed proteins. Protein spots in silver-stained gels 
were analyzed by ANOVA. DA: proteins that showed increased (↑) or decreased (↓) 
expression following dopamine treatment. α-Syn: proteins that displayed increased (↑) or 
decreased (↓) expression as a consequence of α-synuclein overexpression. Complex: proteins 
that displayed altered levels as a result of the association of dopamine treatment with α-










Table 8: MS/MS peptide sequence analysis of successfully identified proteins. The protein 
name, the MS/MS data, the Mascot ion score and the Sequence Coverage are reported. 
a
 start-
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4.1.4 Network enrichment highlights the involvement of the NF-κB 
pathway 
 
Experimentally identified proteins were analyzed in terms of both interaction network and GO 
classification enrichment using PPI spider, a network enrichment algorithm based on known 
protein-protein physical interactions (Antonov et al., 2009). Figure 9 shows significant 
(p<0.05) network models for proteins that displayed significant changes following dopamine 
treatment, regardless of α-synuclein overexpression (A), and for proteins that displayed 
significant changes as a consequence of α-synuclein overexpression or as a result of the 
association of dopamine treatment with α-synuclein overexpression (B). The same analysis 
performed on all identified proteins was able to correctly cluster them in the two classes 
described above. 
Statistically-significant (p < 0.05) functional association to Gene Ontology (GO) 
classifications was obtained from PPI spider starting from proteins grouped as above (Tables 
9 and 10).  
In both cases, bioinformatic analysis revealed that the NF-κB pathway could be involved in 
determining the effects of dopamine treatment and α-synuclein overexpression.  
 
Figure 9: Enriched protein networks. (A) 
Proteins that displayed significant changes 
following dopamine treatment. (B) Proteins 
that displayed significant changes as a 
consequence of α-synuclein overexpression 
or as a result of the association of dopamine 
treatment with α-synuclein overexpression. 
Experimentally identified proteins are 
indicated by filled squares. Open circles 
indicate common interactors as predicted by 
PPI Spider, p < 0.05. Colors indicate 







Table 9: Enriched GO categories starting from proteins that displayed significant changes 
following dopamine treatment, regardless of α-synuclein overexpression. Statistically-
significant (p < 0.05) functional association to Gene Ontology (GO) classifications was 
obtained from PPI spider (http://mips.helmholtz-muenchen.de/proj/ppispider/) starting from 
proteins that displayed significant changes in their levels following dopamine treatment 
(labeled as DA, see Table 7). Genes are labeled with their accession name in the NCBI Gene 
database.  
 
GO term Description Input genes 














Table 10: Enriched GO categories starting from proteins that displayed significant changes 
following α-synuclein overexpression or in a more complex way. Statistically-significant (p < 
0.05) functional association to Gene Ontology (GO) classifications was obtained from PPI 
spider (http://mips.helmholtz-muenchen.de/proj/ppispider/) starting from proteins that show 
quantitative alterations in response to α-synuclein overexpression (labeled as α-Syn, see Table 
7), or that differentially respond to dopamine exposure as a function of α-synuclein 
overexpression (labeled as Complex, see Table 7). Genes are labeled with their accession 
name in the NCBI Gene database.  
 
GO term Description Input genes 




















































4.1.5 Dopamine-induced apoptosis is not affected by α-synuclein 
 
The suggestions obtained from enriched GO categories (Table 10) and the ambiguous role of 
α-synuclein (see Introduction, Paragraph 1.4) prompted us to evaluate apoptotic cell death in 
our experimental setting by Annexin V assay (see Material and Methods, Paragraph 3.1.6). 
Comparing white and black bars of Figure 10, panel A, it is possible to notice that the basal 
level of apoptotic cells was not significantly different in α-syn cells (20.0±1.6%) with respect 
to β-gal cells (23.1±0.7%), in agreement with cell viability assays (see Paragraph 4.1.1). 
Remarkably, also the percentage of necrotic cells was not significantly affected by α-
synuclein overexpression (β-gal cat 16.6±1.3; α-syn cat 14.1±1.5; Figure 10, panel B). 
Dopamine triggered apoptotic cell death to the same extent in both α-syn (α-syn DA, 
45.8±2.6%),  and β-gal cells (β-gal DA, 50.9±2.7%),  (Figure 10, panel A). Also propidium 
iodide positive cells show similar levels in α-syn (α-syn DA, 51.2±5%),  and β-gal cells (β-gal 
DA, 51.7±5%),  (Figure 10, panel B). 
 
 
Figure 10: A) Induction of apoptosis. Apoptotic β-gal and α-syn cells are measured 
as percentage of annexin V positive cells in response to dopamine treatment. ** p < 
0.001 cat vs. DA cells. Values are the mean  SE of three independent experiments. 
B) Percentage of PI positive cells.  
White bars: β-gal cells; black bars: α-syn cells; open bars: 24 h treatment in the 
presence of 700 U/ml catalase only (cat); dashed bars: 24 h treatment in the presence 
of 700 U/ml catalase and 0.25 mM dopamine (DA). Values are the mean  SE of 
three independent experiments. ** p < 0.001 cat vs. DA cells. 






4.1.6 Dopamine and α-synuclein affect the NF-κB pathway 
 
In order to functionally assess the involvement of the NF-κB pathway as suggested by the 
network enrichment procedure of proteomic data (see Paragraph 4.1.4), we transfected β-gal 
and α-syn cells with the pNF-κB-Luc gene reporter and measured the NF-κB-dependent 
luciferase activity (for further experimental detailed see Materials and Methods, Paragraph 
3.1.7).  
As shown in Figure 11, the basal activation of NF-κB was significantly (p< 0.001) lower in α-
syn cells (SH-SY5Y α-syn cat) than in β-gal cells (SH-SY5Y β-gal cat), since the luciferase 
related activity was reduced by 30% (±5%).  
Additionally, after 24 h dopamine treatment, the expression of the reporter gene in β-gal and 
α-syn cells was dramatically decreased, the luciferase activity being reduced by a factor of 10 
(p< 0.001). After 2 h dopamine treatment we did not observe any significant change, neither 
in β-gal nor in α-syn cells (data not shown).  
 
Figure 11: Activation of the NF-κB pathway. NF-κB activity measured by 
luciferase gene reporter assay relative to β-gal cells treated with catalase (set to 1). 






4.1.7 Dopamine, not α-synuclein overexpression, increases the 
expression of HSP70 
 
HSP70 is known to be induced by several stress conditions in the nervous system (Calabrese 
et al., 2004; Garrido et al., 2001) and to inhibit NF-κB activation (Malhotra et al., 2002; 
Salminen et al., 2008). Thus, we measured by Western blotting HSP70 levels in β-gal and α-
syn cells treated or not with dopamine (0.25 mM, 24 h).  
Figure 12 shows that HSP70 basal levels were similar in α-syn (SH-SY5Y α-syn cat) and β-
gal cells (SH-SY5Y β-gal cat). However, dopamine increased HSP70 level 1.5-fold, 




Figure 12: Expression of the NF-κB regulator HSP-70 relative to expression 
observed in β-gal cat cells (set to 1). * p < 0.005 vs. β-gal cat cells. Values are the 









4.1.8 Dopamine does not influence total level of 14-3-3 
 
14-3-3 proteins are ubiquitous eukaryotic acidic polypeptides of ~32 kDa that binds to serine 
or threonine residues of phosphorylated proteins and play a regulatory role in intracellular 
signal transduction, cell-cycle progression, differentiation and apoptosis. In addition, 14-3-3 
shows sequence similarity to α-synuclein, which in turn can bind to 14-3-3, and both α-
synuclein and 14-3-3 have many common interactors (see Introduction, Paragraph 1.4). 
Remarkably, network enrichment revealed a central role for 14-3-3 after both dopamine 
treatment and α-synuclein overexpression (see Paragraph 4.1.4 and Figure 9). Thus, we 
measured 14-3-3 levels by Western blotting in β-gal and α-syn cells treated or not with 
dopamine (0.25 mM, 24 h). As reported in Figure 13, 14-3-3 total levels are similar in α-syn 
(SH-SY5Y α-syn cat) and β-gal cells (SH-SY5Y β-gal cat), even after dopamine treatment 




Figure 13: Expression of 14-3-3 chaperone proteins relative to expression observed 










4.1.9 Dopamine effect on cell cycle 
 
In order to avoid biased conclusions about dopamine toxicity in our model, we considered 
potential differences in cell cycle distribution in our experimental conditions. 
The effects of dopamine (0.25 mM with catalase 700 U/ml) on cell cycle distribution of α-syn 
and β-gal cells are reported in Figure 14. The only detectable effect was a slight increase 
(10%) in the S (p<0.05) and a decrease in the G2/M phase cell subpopulations after 24 h 
exposure to dopamine in β-gal cells. Noticeably, α-synuclein overexpression does not affect 












Figure 14: Effects of dopamine on cell cycle distribution in α-syn and β-gal cells. A) 
Distribution in the different cell cycle phases. Black bars: G0/G1 phase; white bars: 
S phase; shaded bars: G2/M phase. Values are the mean ± SE of three independent 
experiments. * p < 0.05 vs. β-gal cat. B) Representative  histograms for the cell 
cycle analysis. Fluorescent emission of PI is collected through a 575 band-pass 
filter, acquired in linear mode. Gaps are set in the control condition (SH-SY5Y β-gal 
cat) and applied to other samples: M1= G0/G1 phase; M2= S phase; M3= G2/M 






4.1.10  Dopamine downregulates Voltage-Dependent Anion 
Channels 
 
Voltage-Dependent Anion Channels (VDACs) are the most abundant proteins of the outer 
mitochondrial membrane, thus acting as key players in many cellular processes, ranging from 
metabolism regulation to cell death (Celsi et al., 2009). 
In order to validate the qualitative change observed in VDAC2 level in the proteomic analysis 
(see Figure 15 and Paragraph 4.1.3), we evaluated VDAC2 levels by Western blotting after 4, 
7, 12 and 24 h dopamine exposure (see Paragraph 3.1.10). Since mitochondrial impairment is 
a well known pathogenetic mechanism in PD, we investigated how dopamine influenced 




Figure 15: Dopamine downregulation of VDAC2 after 24 h dopamine treatment. A) 
3D representation of spot #173 in 2-DE maps of SH-SY5Y cells treated (DA) or not 
(cat) with 0.25 mM dopamine for 24 h, regardless of α-synuclein overexpression. B) 
Zoom of 2-DE maps of SH-SY5Y cells treated or not with 0.25 mM dopamine for 
24 h in the area of spot #173 (circled), corresponding to VDAC2. 
 
 
Figure 16 shows VDACs levels after 24 h dopamine treatment. VDAC2 disappeared, thus 
confirming two-dimensional electrophoresis results. VDAC3 was completely eliminated, too. 
VDAC1, which is the most abundant form among VDACs family members, was 








Figure 16: Anti-VDAC1, -VDAC2 and -VDAC3 immunoblot in SH-SY5Y cells 
after 24 h dopamine treatment (DA) and in controls (Cat, 700 U/ml catalase, 24h).  
 
To better characterize time-dependent changes of VDACs levels, we performed a time-course 
evaluation of VDACs by Western blotting after 4, 7, 12 and 24 h dopamine exposure.  
 
VDAC1 
As shown in Figure 17, VDAC1 level did not differ significantly in controls, but 
progressively diminished in SH-SY5Y cells treated with 0.25 mM dopamine. The 
downregulation became significant after 12 h, VDAC1 level being further reduced to one 
third (compared to Cat 24h) after 24 h. 
 
Figure 17: Upper panel: Expression of VDAC1 relative to expression observed in 
SH-SY5Y cells cat 4h (set to 1). Values are the mean  SD of three independent 








As shown in Figure 18, VDAC2 level differed significantly also in controls and progressively 
increases in SH-SY5Y cells maintained in culture (similar behavior was observed in the 
absence of catalase, data not shown). After 24 h (Cat 24 h), VDAC2 level was raised 2-fold 
compared to Cat 4h cells. In dopamine-treated cells the downregulation became significant 




Figure 18: Upper panel: Expression of VDAC2 relative to expression observed in 
SH-SY5Y cells cat 4h (set to 1). Values are the mean  SD of three independent 





Due to the low expression level of VDAC3 compared to VDAC1 and VDAC2 and 
considering the low specificity/sensitivity of anti-VDAC3 antibody used here, the time course 
analysis of VDAC3 response to dopamine treatment did not give reproducible results, thus 






TOTAL NUMBER OF MITOCHONDRIA 
 
To verify that VDACs downregulation was not due to a general decrease in the number of 
mitochondria, we determined the level of other mitochondrial proteins, such as grp75 and 
HSP60 (see Figure 19). 
Western blotting analysis did not show changes in their levels, neither in controls (culture 
time effect) nor in SH-SY5Y dopamine-treated cells for different times (treatment effect), 
thus confirming a specific effect of dopamine on VDACs expression. 
 














4.1.11 Two-dimensional Western blotting of VDAC2 reveals a 
treatment-dependent phosphorylated form 
 
To observe possible post-translational modifications of VDAC2, we performed a two-
dimensional Western blotting. Indeed, in one-dimensional Western blotting of VDAC2 we 
observed a high standard deviation in DA 4h samples (see Figure 18); thus, the observation of 
a diffuse band prompted us to hypothesize the presence of different forms migrating at similar 
molecular weight and immunoreactive to anti-VDAC2 antibody. 
Immunoblot was performed after 4 and 7 h, VDAC2 becoming undetactable after 7 hours of 
dopamine treatment (see Paragraph 4.1.10). 
As shown in Figure 20, VDAC 2 migrated at pH ≈ 8 (VDAC2 4h Cat), as expected 
(theoretical pI= 7.66). After 4 hours of dopamine treatment the prevalent form of VDAC2 was 
the more acidic one, with a pI ≈ 7 (VDAC2 4h DA). When present in controls, the acidic form 
was always a spot with a lower intensity with respect to the main form at pH 8. 
After 7 h, the more acidic form became appreciable in controls too, although the main form 
still remained the one at pH ≈ 8 (VDAC2 7h Cat). In dopamine-treated cells, on the other 
hand, VDAC2 was strongly downregulated and the only form being observed here is the 
acidic one. Remarkably, the more acidic form has been reported to be the phosphorylated 




Figure 20: Two-dimensional immunoblot anti VDAC2 
of SH-SY5Y cells treated with 700 U/ml of catalase only 
(Cat) or with 700 U/ml catalase + 0.25 mM dopamine 
(DA) for 4 h (upper panel) and for 7 h (lower panel). 






4.1.12  Dopamine alters the mitochondrial membrane potential 
 
Since VDACs are porins of the outer mitochondrial membrane, we measured the membrane 
potential with the TMRM potentiometric staining (see Paragraph 3.1.11). TMRM is a 
positively charged molecule that accumulates in mitochondria when their membrane potential 
(ΔΨm) is normal (negatively charged). If the potential drops down, the mitochondria become 
barely visible. 
Figure 21 left shows TMRM-stained mitochondria in SH-SY5Y cells treated for 24 h with 
700 U/ml catalase only (Cat). Conversely, right panel displays a marked depolarization of the 
mitochondrial membrane as a consequence of 24 h 0.25 mM dopamine exposure (DA). 




Figure 21: TMRM staining of SH-SY5Y cells treated with 700 U/ml of catalase 
only (Cat, left panel) or with 700 U/ml catalase + 0.25 mM dopamine (DA, right 






4.1.13  Dopamine alters calcium flux to mitochondria 
 
VDACs mediate the flow of ions and metabolites between the cytoplasm and the 
mitochondrial network and regulate Ca
2+
 signaling (Celsi et al., 2009). In this respect we 
measured the flow of Ca
2+
 to the mitochondria in dopamine treated cells, taking into account 
the downregulation of VDACs. Recombinant aequorin was targeted to the mitochondria 
(mtAEQ) to reveal calcium flux to mitochondria and 100 nM bradykinin was used as a trigger 
to detect a peak in this flux (see Material and Methods, Paragraph 3.1.12). 
In Figure 22 are reported different traces of calcium mitochondrial influx measurements in 
control conditions (black, Cat) and following 24 h dopamine treatment (red, DA). The 
calcium flux to mitochondria was reduced by dopamine to 75% of the basal value after 24 h 
as it is possible to observe in Figure 23, lower panel, where the mean and standard deviation 
of 14 different experiments are reported. Calcium mitochondrial influx was not influenced by 








]m measurements in SH-SY5Y 
cells, transfected with mitochondria-targeted aequorin, are shown. Left, black traces: different [Ca
2+
]m 
measurements of control condition replicates (700 U/ml catalase, 24 h). Right, red traces: different [Ca
2+
]m 
measurements of treated cells condition replicates (700 U/ml catalase + 0.25 mM dopamine for 24h). Ca
2+
 influx 









Figure 23: Effect of dopamine treatment on relative mitochondrial Ca
2+
 uptake after 4 h (upper panel) or 24 h 
0.25 mM dopamine exposure (lower panel). Black bars refer to SH-SY5Y cells treated with 700 U/ml catalase 
only; red bars refer to SH-SY5Y cells treated with 700 U/ml catalase + 0.25 mM dopamine. Values are 
normalized to the reference condition (Cat 4 h and 24 h, respectively), set to 1. Bars represent the mean  SD of 







4.1.14 Dopamine specifically affects the two-dimensional pattern of 
DJ-1 
 
SH-SY5Y model has been further exploited to better characterize cellular responses to altered 
dopamine homeostasis. DJ-1 is a well documented reporter of this condition (see Introduction, 
Paragraph 1.5). 
We chose to investigate changes in the 2-DE pattern of DJ-1 following 24 h treatment with 
0.1 mM dopamine (for experimental details see Materials and Methods, Paragraph 3.1.13), a 
concentration that did not increase intracellular ROS levels (data not shown). Under these 
conditions, we observed the occurrence of 5 main spots (pI = 5.8, 6.0, 6.3, 6.6, and 6.8) 
progressively numbered from -2 to 2 on going from the acidic to the basic side of the pattern, 
with spot 0 corresponding to the central and most intense one (Figure 24, Panel A). Each spot 
was observed to be present in all replicates and under both experimental conditions, although 
the relative intensity of the most acidic (-2) and most basic (2) spot was significantly affected 
by dopamine treatment (Figure 24, Panels B and C). In particular, a marked reduction of spot 
2 was observed, whereas spots -2, fairly visible under control conditions, and -1 were 
significantly enhanced. No significant differences were observed after 48 h dopamine 
exposure for each spot with respect to 24 h exposure. As a positive control, we treated cells 
with 1.0 mM H2O2, 15 min (see Figure 25). Upon treatment with a strong oxidizing agent a 
new basic form appeared, which in turn was barely detectable following dopamine treatment. 
Conversely, a marked increase in acidic forms was observed, in agreement with what reported 
in the literature (Mitsumoto and Nakagawa., 2001; Mitsumoto et al., 2001).  
Three main forms are reported in the literature in the absence of a dopamine challenge. Figure 
24, Panel D shows a meta-gel, i.e., an average intensity projection image, wherein each pixel 
stores the average intensity in the 6 original images (Bandopadhyay et al., 2004; Canet-Avilés 
et al., 2004; Colapinto et al., 2006; Motani et al., 2008) at corresponding pixel location. The 
color scale of this meta-gel accounts for the occurrence frequency of each spot in the 
considered experiments, with less frequent spot positions in blue and more frequent spot 
positions in white. In the absence of dopamine challenge, the acidic spot -2 is 








Figure 24: The two-dimensional electrophoresis 
pattern of DJ-1. Panel A: Representative two-
dimensional anti-DJ-1 immunoblots of proteins 
extracted from human neuroblastoma SH-SY5Y 
cells. Upper row: control; middle row: 0.1 mM 
dopamine. All treatments were performed for 24 
hours unless specified otherwise. Spots observed at 
pI= 5.8, 6.0, 6.3, 6. 6, and 6.8 were progressively 
labeled with a number from -2 to 2. Panel B: 
Synthetic image of average distribution of DJ-1 
isoforms. Upper row: control; lower row: 0.1 mM 
dopamine. Panel C: Relative intensity of DJ-1 spots. 
Each intensity is normalized with respect to total 
intensity. Values are the mean  SD of three 
independent experiments. White bars: control; black 
bars: 0.1 mM dopamine. * p < 0.05 vs. controls; ** p 
< 0.001 vs. controls. Panel D: meta-gel of DJ-1 








Figure 25 Oxidative modifications in the two-dimensional 
electrophoresis pattern of DJ-1. Representative two-
dimensional anti-DJ-1 immunoblots of proteins extracted 
from human neuroblastoma SH-SY5Y cells. Control: fresh 
medium for 15 min; H2O2: 1.0 mM H2O2 in fresh medium 
for 15 min. Spots observed at pI= 5.8, 6.0, 6.3, 6.6, and 6.8 






4.2 DOPAMINE RESPONSE OF DOPAMINERGIC CIRCULATING CELLS: 
THE JURKAT CELL MODEL 
4.2.1 Jurkat cells possess a complete dopaminergic system 
 
To investigate the nature of the dopaminergic system in Jurkat cells, we evaluated the mRNA 
expression of D1, D2(1) and D2(2) splicing variants, D3(a) splicing variant, D4 and D5 
receptors, DAT, VMAT1 and VMAT2 transporters and TH (Figure 26, upper panel). We 
selectively evaluated the D3(a) level because the D3(e) splicing isoform does not bind 
dopamine (Missale et al., 1998). Detectable transcript levels of D1, D2(1), D3(a) and D5 
receptors, as well as of DAT, VMAT1 and VMAT2 transporters, allowed us to establish the 
occurrence of a complete dopaminergic system in Jurkat cells. The appropriateness of primers 
and RT-PCR conditions was verified by checking the expression of the dopaminergic system 
components in the catecholaminergic human neuroblastoma SH-SY5Y cell line (Figure 26, 






Figure 26: Expression at the transcriptional level of the dopaminergic system 
components in Jurkat T leukemic cells and neuroblastoma SH-SY5Y cells (as 
positive control). Receptors D1, D2(1) and D2(2) splicing variants, D3(a) splicing 
variant, D4 and D5, transporters VMAT1, VMAT2 and DAT, and TH in Jurkat cells 
(upper panel) and SH-SH5Y cells (lower panel) are visualized on a 2% agarose gel 
stained with ethidium bromide after RNA extraction, reverse transcription and PCR 







4.2.2 Proteomics analysis reveals quantitative changes in 7 proteins 
 
Dopamine challenge of Jurkat cells induced quantitative changes in the protein expression 
pattern, as deduced by image analysis of 2-DE gels (Figure 27). A 50 μM dopamine 
concentration was chosen in order to stimulate all receptors and to load cells through the DAT 
and VMAT transporter system. On the other hand, the dopamine concentration is limited by 
the appearance of oxidative stress conditions associated to dopamine auto-oxidation (Alberio 
et al., 2010b). Cell viability was not affected by the treatment (data not shown), thus 
confirming that the chosen concentration was not toxic. We observed reproducible changes in 
the level of 7 spots (Student's t test) that were further analyzed by peptide mass fingerprinting. 
Consequently, we were able to establish that calreticulin and 14-3-3 ε were downregulated by 
dopamine treatment, whereas STI1, a basic isoform of β/γ actin, phosphoglycerate mutase 1, 
HSP60 and TCP1θ were upregulated (Table 11).  
 
Table 11: Identification of differentially expressed proteins in Jurkat cells challenged with 50 
μM dopamine. a Uniprot database; b Theoretical values; c Student's t test. FI: Fold of 





















1 Calreticulin P27797 47.9 4.29 2.72 ↓ 0.02 30 83 
2 14-3-3 ε P62258 29.2 4.63 2.30 ↓ 0.05 34 74 
3 STI1 P31948 62.6 6.40 1.78 ↑ 0.05 34 119 




P18669 28.7 6.75 1.65 ↑ 0.02 46 131 
6 HSP60 P10809 58.0 5.24 1.47 ↑ 0.01 24 62 







Figure 27: Representative spots in a synthetic two-dimensional gel of proteins 
extracted from whole Jurkat cells. The synthetic gel is obtained from Coomassie 
stained gels (three replicates per experimental condition) by averaging the 
normalized volumes of spots present in all considered gels. Greyscale refers to mean 
spot volumes. Spots which display a significant change in intensity after dopamine 
challenge (50 μM, 24 h) are numbered. Insets report the mean percent spot volumes 
 SE in three different gels. Open bars: control cells; filled bars: dopamine treated 
cells. For protein identifications see Table 11. For further details and experimental 







4.2.3 Network enrichment procedure underlines the importance of a 
chaperone proteins network  
 
In order to build a comprehensive model to encompass the experimentally identified proteins, 
we analyzed the entire list in terms of both interaction network and GO classification 
enrichment using PPI spider (Antonov et al., 2009) (see Materials and Methods, Paragraph 
3.2.5).  
A significant (p<0.05) enriched network for proteins altered by the dopamine challenge is 
reported in Figure 28. A significant functional association to Gene Ontology (GO) class 




Figure 28: Protein-protein interaction network enrichment. Filled squares refer to 
experimentally identified proteins, whereas empty circles indicate enriched proteins 
(common interactors). The network enrichment procedure was performed using 







4.2.4 Dopamine modifies the two-dimensional pattern of β-actin and  
14-3-3 
 
The observation of a significant change in a basic isoform of β/γ actin (see Paragraph 4.2.2) 
appeared quite unusual. Therefore, we proceeded to validate the finding by two-dimensional 
Western blotting. Actually, dopamine treatment markedly affected the 2-DE pattern of β/γ 
actin with a shift towards basic forms (Figure 29, panel A). 
Two members of the 14-3-3 chaperone family seemed to be affected by dopamine treatment: 
2-DE analysis revealed the upregulation of 14-3-3 ε (Figure 27), whereas the network 
enrichment procedure assigned a central role to 14-3-3 δ (Figure 28). To confirm both 
findings, we performed two-dimensional Western blotting using an antibody that recognizes 
all 14-3-3 isoforms (Figure 29, Panel B). Dopamine treatment induced a global change in 
isoform distribution. Images were acquired using two different exposure times, in order to 
discriminate differences in both low- and high-abundance species. By saturating the main 
component, we were able to observe the downregulation of minor spots following dopamine 
treatment (Figure 29, Panel B, left). By lowering the exposure time, on the other hand, the 
most abundant isoforms appeared as four resolved spots. In this pattern, dopamine 




Figure 29: Two-dimensional 
Western blot analysis of β-actin 
and 14-3-3 isoform patterns. Panel 
A: alteration of the β-actin pattern 
in control (upper row) and 
dopamine-treated cells (50 μM, 24 
h, lower row). Panel B: alteration 
of the 14-3-3 pattern in control 
(upper row) and dopamine-treated 
cells (lower row) at different 
exposure times (left: 20 sec; right: 
5 sec). Results were confirmed by 
three independent replicates. For 
further details and experimental 











Clinical research takes advantage of basic neurobiology research mainly when dealing with 
two aspects: the characterization of biochemical mechanisms at the ground of the disease 
onset and progression, and the identification of biomarkers, which in turn could help in 
following the clinical response to new therapeutic agents. These two aspects, that define the 
framework of the present thesis, are actually two sides of the same extent to improve the 
clinical approach to the disease and to give to basic research a translational meaning (Alberio 
et al., 2010a, 2010b). The ways of dealing with this important challenge are substantially two: 
a targeted approach or a widespread approach. Of course, in the first case valid hypotheses 
raising from other studies need to be available and the new goal is that of validating them or 
giving a deeper molecular characterization of the phenomenon (hypothesis-driven method). 
The second is, on the contrary, an hypothesis-generating method, descriptive at the very 
beginning to become mechanistic in the foreground, to functionally characterize the 
observations made in the first part. 
The case of Parkinson's disease is a clear example of the advantages of an unbiased, 
hypothesis-generating approach. PD is a progressive neurological disorder whose causes are 
unknown, but considerable evidence suggests a multifactorial etiology involving genetic and 
environmental factors. Moreover, pathogenesis has not yet been clarified even if many 
aspects, such as oxidative stress, mitochondrial dysfunction, excitotoxicity, glia 
hyperactivation and apoptosis, have been investigated in the last decades. Understanding the 
mechanisms at the basis of neurodegeneration in PD would then request an a priori 
speculation on probable causes and pathological cascades that follow. To bypass this initial 
bias the emerging field of neuroproteomics promises to provide powerful strategies to further 
characterize neuronal dysfunction and cell loss associated with neurodegenerative diseases 
(Becker et al., 2006). Several papers have been published in the last years on the pathogenetic 
mechanisms of neurodegenerative disorders, with a focus on Alzheimer‟s disease (AD) (Sheta 
et al., 2006) and Parkinson‟s disease (PD) (see Fasano et al., 2007 and Robinson, 2010).  
Proteomics is a powerful methodology to investigate how protein expression is affected in the 
pathogenesis and is a technology-driven approach that takes advantage from unprecedented 
advances in separation techniques such as two-dimensional electrophoresis and liquid 
chromatography, in the design and exploitation of high-sensitivity sources and analyzers for 
mass spectrometry, and in bioinformatics. These advances have allowed the quantitative 
analysis of protein levels and post-translational modifications that altogether help to 






etiology, progression, outcome, and response to therapy. On the other hand, proteomics 
provides a high-throughput methodology for the search of new therapeutic targets. 
As a whole, the proteomic methods are a valuable toolbox for either the analysis of 
pathogenetic mechanisms in neurodegenerative disorders and (cell and animal) models 
thereof, or the search for suitable biomarkers that should be useful for early and differential 
diagnosis as well as for therapy assessment. 
 
A SH-SY5Y MODEL TO INVESTIGATE PD PATHOGENETIC MECHANISMS 
 
A common issue in proteomic investigations of PD models is the choice of the best suited 
model system to be used in the study. In vitro models represent the more controlled 
environment systems for proteomic analysis, but may lack the cellular microenvironment 
critical to disease development, and the cell type chosen may not express the particular 
protection systems expressed in cells such as dopaminergic cells. Similar to established cell 
lines, primary cells must adapt to grow in culture conditions, which will be reflected by 
continuous changes in the cellular proteome. The longer they are in culture, the more the 
proteome is likely to change. The use of inducible pluripotent stem cells derived from 
inherited and sporadic patients may be particularly useful to look for evidence of subtle 
background genetic influences on disease development. 
By contrast, animal models offer a microenvironment more akin to that of humans, although 
differences in brain structures and methods used to induce parkinsonism constitute an 
important limit. Though, they can be very useful for answering specific questions, such as 
changes to the expression of proteins that specifically affect dopaminergic neurons or cause 
some of the phenotypic changes observed in PD. Combining these limitations with the 
potential absence of other key environmental factors make the creation of an accurate model 
of disease difficult to develop. Consequently, the model used to address a particular question 
always needs to be considered carefully. The analysis of human tissue may be useful, but also 
has limitations. Difficulties in the acquisition of a suitable number of autoptic specimens from 
PD affected individuals strongly limited proteome analysis of human brain areas of PD 
patients. Moreover, human tissue samples are heterogeneous from patient to patient, which 
increases the difficulty of identifying changes in protein expression for a specific disease 
state. Another important point is that patient tissue samples often can provide information at 







Taking into account all these difficulties, we chose to use the catecholaminergic SH-SY5Y 
human neuroblastoma cell line to address a specific pathogenetic mechanism related to altered 
dopamine homeostasis, being aware that we could simply mimic a particular aspect of a 
complicated, multifactorial disease, such as PD. SH-SY5Y cells express the DA transporter 
(DAT) and DA receptors and are able to form storage vesicles, although the low activity of 
the vesicular monoamine transporter type 2 impairs DA storage into vesicles. For this reason, 
SH-SY5Y cytoplasmic DA concentration may be increased by administering DA in the 
culture medium (Gomez-Santos et al., 2003, Fasano et al., 2008a). The optimal concentration 
of dopamine to be used in this study was determined by MTT assay (see Results, Figure 6) 
Following 0.25 mM dopamine exposure, both β-gal and -syn cells displayed about 70±5% 
viability. Since the percentage of viable cells was still acceptable to conduct the proteomic 
analysis and the toxicity was almost identical for the two cell lines, the concentration chosen 
for all further experiments was 0.25 mM. Cells were always exposed to dopamine in the 
presence of 700 U/ml catalase to eliminate aspecific effects due to H2O2 arising from 
dopamine auto-oxidation (Blum et al., 2000). 
Additionally, SH-SY5Y cells were stably transformed to enhance expression of wild-type α-
synuclein. Unlike transient expression reported in the literature that leads to protein 
aggregation and increased susceptibility to DA toxicity, stable (i.e., at sub-toxic level) 
expression of wild-type α-synuclein avoid problems linked to an excessive expression that 
inevitably leads to fibrillation and cell death (Colapinto et al., 2006). As a control, we used 
SH-SY5Y cells stably transfected with the plasmid containing β-galactosidase cDNA (β-gal). 
We intentionally did not clone the cell lines to avoid working with only few clones and 
raising the possibility to study cells different from those originally selected. Because it is 
known from literature that dopamine upregulates α-synuclein expression (Gomez-Santos et 
al., 2003), we measured the level of α-synuclein in α-syn cells with respect to β-gal cells after 
dopamine exposure. Interestingly, dopamine treatment significantly increased the expression 
of α-synuclein in β-gal control cells but not in α-syn cells that already overexpress it owing to 
transfection (see Results, Figure 7). If a small increase in α-synuclein levels is protective, a 
further induction in α-syn cells is not necessary following dopamine treatment. 
Proteomic investigations were conducted on β-gal and α-syn cells treated or not with 
dopamine, giving rise to four experimental conditions. Through the comparison of treated and 






comparing β-gal and α-syn cells it is possible to appreciate the effect of α-synuclein 
overexpression, while taking into account all the different conditions at the same time permits 
to reveal proteins whose levels are modified by the combination of the two factors. Statistical 
analysis (by two-way ANOVA) of silver-stained gel images revealed 28 spots whose intensity 
was significantly different in at least one of the four groups considered (see Results, Figure 
8).  
 
Proteins differentially expressed in this model are individually linked to PD 
Most of the identified proteins may be linked to different pathogenetic mechanisms in PD, 
either specific or associated to generic stress conditions. Upregulation of peroxyredoxin 1 is 
in keeping with increased ROS production by dopamine oxidation that activates apoptosis and 
together induces the synthesis of antioxidant (Lev et al., 2009) and anti-apoptotic factors 
(Mattson, 2000). Higher glycolytic activity is shown by higher aldolase A, enolase 1 and 
pyruvate kinase levels together with lower parathymosin level (Brand and Heinickel, 1991). It 
should be noticed, however, that quantitative alterations of glycolytic enzymes are frequently 
observed following a generic stress event (Petrak et al., 2008). Two groups of spots showing 
remarkable changes in the isoform pattern in the four conditions were easily assigned to 
glyceraldehyde-3-phosphate dehydrogenase and to mitochondrial ATP synthase alpha subunit 
by comparison with 2-DE maps available in the SWISS 2D-PAGE database. Variations of 
ATP synthase A and GAPDH isoforms, but not in their total level, could reflect a proteome 
adaptation as a response to perturbation of protein levels caused by stimuli of different origin 
(Mao et al., 2007). In parallel, proteins involved in protein synthesis, i.e., eIF5A, RPLP2 and 
its mitochondrial paralog L7/L12, were less abundant, suggesting attenuated translation at 
both cytoplasmic and mitochondrial level under cellular stress conditions (Shenton et al., 
2006). Proteins involved in cytoskeleton structure and regulation were found in both groups 
(proteins whose level change on account of dopamine treatment or of α-synuclein 
overexpression). Cytoskeleton dysregulation was suggested to be an early event in PD 
pathogenesis, as alterations in either cytoskeleton components or regulatory proteins were 
reported in a fruitfly model expressing mutant α-synuclein in the early postnatal days (Xun et 
al., 2007). Dopamine induced an increase of fascin 1, a regulator of the organization of 
filamentous actin into bundles (Tseng et al., 2005). Comparison with 2-DE image databases 
assigned this spot to the phosphorylated, inactive form of fascin 1 (Aratyn et al., 2007). 






associated proteins, namely annexin A2 and annexin A5, both acting on regulation of 
membrane dynamics, cell migration, proliferation and apoptosis (Monastyrskaya et al., 2009), 
and contributing to the regulation of neural development (Naciff et al., 1996). Profilin 1, 
another regulator of the actin cytoskeleton that is necessary for neuronal differentiation and 
synaptic plasticity (Birbach, 2008), is upregulated in α-syn cells. Also in this case, 
comparison of the experimental maps with those available in 2-DE image databases indicates 
that the spot relative to profilin 1 corresponds to the phosphorylated protein, showing 
increased affinity for G-actin with a consequent destabilization of the actin cytoskeleton 
(Sathish et al., 2004). It has been recently reported that α-synuclein binds actin, slowing down 
its polymerization and accelerating its depolymerization, thus suggesting a role of α-synuclein 
in actin dynamics (Sousa et al., 2009). Moreover, we observed decreased levels of 
(dephosphorylated) stathmin 1 in α-syn cells. This protein destabilizes microtubules, thus 
accounting for their dynamics, and regulates cell cycle progression by acting on the mitotic 
spindle (Andersen, 2000). In this context, increased levels of lamin A/C both after dopamine 
treatment and α-synuclein overexpression can be signs of a more complex regulation possibly 
involving physical contacts between the nuclear structure and cytoskeletal proteins (Broers et 
al., 2006). Lamin levels could also change in response to oxidative stress conditions as lamin 
A/C is more phosphorylated and forms a complex with molecular chaperone HSP90 in 6-
hydroxydopamine-treated SH-SY5Y cells (Nakamura et al., 2009). 
Besides cytoskeleton-related proteins, an increase of GSTπ was observed in -syn cells. 
GSTπ polymorphism is associated with PD both in humans after pesticide exposure 
(Menegon et al., 1998) and in a Drosophila model expressing mutant parkin (Whitworth et 
al., 2005). GSTπ expression is responsible for nigral neuron sensitivity in an experimental 
model of PD (Smeyne et al., 2007) and quantitative changes in GSTπ levels were observed in 
SNpc specimens of PD patients by proteome analysis (Werner et al., 2008). 
Alterations in mitochondrial proteins, on the other hand, are specifically linked to one of the 
major pathogenetic mechanisms of PD (Henchcliffe and Beal, 2008) and our proteomic 
analysis showed that mitochondrial activity is affected. Mitofilin plays a fundamental role in 
the maintenance of mitochondrial cristae structure (John et al., 2005), and is covalently 
modified by dopamine oxidation products (Van Laar et al., 2009). Mitofilin interacts with 
PINK1 (PTEN-induced putative kinase 1) (Weihofen et al., 2009), an ubiquitous kinase 
associated to a familial, early-onset PD form (Valente et al., 2004). Mitochondrial p32 (i.e., 







localized in mitochondria, it also localizes at the cell surface and
 
in the nucleus where it acts 
as a multifunctional chaperone
 
for several ligands (Bialucha et al., 2007).  
Another cellular process coming out from our proteomic analysis was the control of Wnt/β-
catenin pathway, associated to neurite outgrowth and synaptic plasticity (Endo and Rubin, 
2007). In the absence of a Wnt signal, β-catenin is targeted to degradation by phosphorylation 
by glycogen synthase kinase-3β (GSK-3β), a multifunctional kinase involved in various 
neuronal functions (Takashima, 2009). Following a Wnt signal, β-catenin is imported into the 
nucleus through RanGTP-dependent transport and activates the transcription of target genes 
by recruiting other factors such as the histone acetyltransferase RuvB-like 1 (Tip49/pontin). 
Levels of the RAN binding protein 1 were reduced in α-syn cells with respect to β-gal cells, 
regardless of dopamine treatment, and RuvB-like 1 is upregulated in α-syn cells in the 
absence of dopamine, thus suggesting a potential role of the Wnt/β-catenin pathway. 
Noticeably, the anti-apoptotic action of parkin in dopaminergic neurons has been associated 
to the regulation of excessive Wnt/β-catenin signalling by blocking Wnt/β-catenin-induced 
cell cycle re-entry and apoptosis, two events that are deregulated in PD (Rawal et al., 2009). 
CRMP4 (collapsin response mediator protein 4), observed here to be significantly reduced in 
α-syn cells, is a member of a family of neuron-enriched proteins that regulate neurite 
outgrowth and growth cone dynamics. Interestingly, CRMP4 is also a substrate of GSK-3β 
(Cole et al., 2006). 
The more evident qualitative change observed after dopamine treatment both in β-gal and α-
syn cells was the complete disappearance of one spot (see Results, Figure 15), corresponding 
to the protein VDAC-2, a porin of the outer mitochondrial membrane that regulates 
mitochondrial Ca
2+
 homeostasis, thus controlling mitochondrial-dependent cell death (Celsi et 
al., 2009). This reduction, already associated to dopamine-induced apoptosis (Premkumar and 
Simantov, 2002), could affect the outer membrane electrochemical potential with consequent 
impairment of mitochondrial function and calcium homeostasis, major pathogenetic 
mechanisms of neurodegeneration in PD (Celsi et al., 2009; Chan et al., 2009). 
 
A focus on Voltage-dependent anion channels role 
Because of the great importance of mitochondrial dysfunction in PD pathogenesis, we further 
investigated dopamine-induced VDAC2 downregulation, also considering VDAC1 and 
VDAC3, to get more insight on their correlation with dopamine altered levels and on their 






synuclein overexpression, we performed this focused investigation on SH-SY5Y wild type 
cells. 
First of all, we confirmed that VDAC2 completely disappeared after 24 hours dopamine 
treatment (0.25 mM) and observed that also VDAC1 and VDAC3 had a similar behavior (see 
Results, Figure 16). Since all VDACs were downregulated, we verified that no change in 
mitochondria number occurred. The level of other mitochondrial proteins (grp75, HSP60; see 
Results, Figure 19), was not affected by dopamine treatment, thus confirming that the effect 
observed was specific for these proteins. However, even if the number of organelles remained 
the same, mitochondria displayed loss of the membrane potential in dopamine-treated cells 
(see Results, Figure 21). In our model, dopamine accumulation in the cytosol and its 
oxidation generates oxidative stress, ROS production and complex I impairment (inhibited by 
dopamine-quinone), thus accounting for the decreased mitochondrial membrane potential. It 
is well established that mitochondria have a pivotal role in the apoptotic cell death pathway; 
when the outer mitochondrial membrane is rendered permeable by the action of „death 
agonists‟, such as Bax, cytochrome c is released into the cytosol, leading to caspase activation 
and apoptosis. Similar pathways are also activated by opening of the mitochondrial 
permeability transition pore, an event that can occur under conditions of oxidative stress or 
electron transport chain inhibition, leading to collapse of the mitochondrial membrane 
potential (Henchcliffe and Beal, 2008). VDACs have been implicated as essential mediators 
of mitochondrial-dependent cell death by functioning as a channel-forming unit within the 
mitochondrial permeability transition (MPT) pore and targets of Bcl-2 family members; 
nevertheless, mitochondria from VDAC1-, VDAC3-, and VDAC1/VDAC3-null mice 
exhibited a Ca
2+
 and oxidative stress-induced MPT that was indistinguishable from wild type 
mitochondria. Similarly, Ca
2+
 and oxidative-stress-induced MPT and cell death was unaltered 
or even exacerbated in fibroblasts lacking VDAC1, VDAC2, VDAC3, VDAC1/3, and 
VDAC1/2/3. Wild type and VDAC-deficient mitochondria and cells also exhibited equivalent 
cytochrome c release, caspase cleavage, and cell death in response to Bax and Bid activation. 
These results indicate that VDACs are dispensable for both MPT and Bcl-2 family member-
driven cell death (Baines et al., 2007). This is in agreement with our observation that 
dopamine-treated cells underwent apoptosis (see Results, Figure 10), despite of VDACs 
downregulation. 
To better characterize time-dependent changes of VDACs levels, we performed a time-course 






VDAC2 downregulation appears more gradual than that of VDAC1, which in turn occurs 
later and to a lesser extent. Due to the low expression level of VDAC3 compared to VDAC1 
and VDAC2 and considering the low specificity/sensitivity of anti-VDAC3 antibody used, the 
time course analysis of VDAC3 response to dopamine treatment did not give reproducible 
results. It is worth to note that VDAC2 level increases in control cells as a time-depending 
effect. One possible explanation of this observation, supported by ongoing experiments, is 
that VDAC2 upregulation could be associated to activation of autophagy as a response to a 
decrease of nutrients in cell culture. 
VDACs mediate the flow of ions and metabolites between the cytoplasm and the 
mitochondrial network and regulate Ca
2+
 signaling (Celsi et al., 2009). In this respect, we 
measured mitochondrial Ca
2+
 influx in dopamine-treated cells. The calcium flux to 
mitochondria is reduced to 75% of the basal value after 24 h dopamine exposure, probably 
mirroring VDACs downregulation. Accordingly, after 4 h dopamine exposure there is no 
difference in Ca
2+
 flux between controls and dopamine-treated cells, in agreement with the 
observation that VDACs are not considerably downregulated, (see Results, Figures 22 and 
23).  
To take into account possible post-translational modifications of VDAC2 that would in some 
way target the protein to degradation, we performed a two-dimensional Western blotting. 
Indeed, in one-dimensional Western blotting of VDAC2 we observed a high standard 
deviation in SH-SY5Y cells after 4 h dopamine treatment; thus, the occurrence of a diffuse 
band prompted us to hypothesize the presence of different forms migrating at similar 
molecular weight and immunoreactive to the anti-VDAC2 antibody. Immunoblots were 
performed after 4 and 7 h, VDAC2 becoming undetactable after 7 hours of dopamine 
treatment. VDAC2 migrates at pI ≈ 8, as expected (theoretical pI= 7.66), but after 4 h 
dopamine exposure a more acidic VDAC2 form becomes prevalent, with a pI ≈ 7. When 
present in controls, the acidic form was always a spot with a lower intensity than the main 
form at pH 8. After 7 h, the more acidic form becomes appreciable in controls too, although 
the main form still remains the one at pH ≈ 8. In dopamine-treated cells, on the other hand, 
VDAC2 is strongly downregulated and the only form being observed here is the acidic one. 
Remarkably, the more acidic form has been reported to be the phosphorylated form (Sarioglu 
et al., 2008). In the same paper, Sarioglu and coworkers demonstrate that treatment of 5L cell 
line with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) causes an upregulation of VDAC2 total 






correlate the appearance of VDAC2 phosphorylated form with its disposal process. 
Additionally, we examined the X-ray structure of VDAC1 (PDB code 2K4T; Hiller et al., 
2008) and annotated on the structure all the putative phosphorylation sites (Distler et al., 
2006; Pastorino et al., 2005) by multiple sequence alignment (Figure 30). Thr51 is a 
conserved residue in all VDACs, and it was reported to be phosphorylated by GSK3β (Das et 
al., 2008). As already discussed, GSK3β involvement is also suggested by the results of the 
proteomic analysis and the hyper-activation of this kinase has already been related to 
neurodegeneration, being involved in Tau phosphorylation (Hernández et al., 2009).  
To characterize the possible involvement of GSK3β in phosphorylating VDAC2 in our model, 
we used the specific GSK3β inhibitor TDZD-8. Preliminary data on VDAC2 phosphorylation 
by GSK3β show that dopamine enhances VDAC2 phosphorylation by GSK3β. Nonetheless, 
this finding does not appear to be a key event for VDAC2 disposal, as dopamine-induced 
VDAC2 downregulation was not blocked by GSK3β inhibition (data not shown). Further 
experiments are needed to confirm these data, to understand the role of GSK3β in our model 






Figure 30: The structural model of VDACs shows their structure and putative 
phosphorylation sites, obtained by multiple sequence alignment of the three VDACs 
sequences. 
 
a) CaMKII e GSK3 consensus (Distler et al., 2006) 
b) PKC  consensus (Distler et al. , 2006) 
c) VDAC2 phosphorylated by INSR (Distler et al. , 2006) 
d) VDAC3 phosphorylated by CKI e PKA (Distler et al. , 2006) 
e) VDAC3 phosphorylated by PKC (Distler et al. , 2006)  







A recent paper suggests that VDAC1 is ubiquitinylated through Lys27-linked chains, 
following mitochondrial membrane depolarization. The authors also show that silencing of 
endogenous VDAC1 by siRNA disrupts the redistribution of Parkin to damaged mitochondria 
and prevents mitochondrial clearance. Both effects could be restored by re-transfection with 
wild type VDAC1, indicating that the mitochondrial substrate VDAC1 is required for proper 
PINK1/parkin-directed mitophagy (Figure 31) (Geisler et al., 2010; Wild and Dikic., 2010). 
This latter result points to an important role for VDAC1 in the formation of this trimeric 
complex, in addition to being a parkin substrate. 
 
 
Figure 31: Model of PINK1/parkin-mediated mitophagy. In the absence of 
mitochondrial damage, E3 ligase parkin is diffusely distributed throughout the 
cytosol. Upon mitochondrial membrane depolarization, PINK1, a kinase of the outer 
mitochondrial membrane (OMM), induces parkin translocation to stressed 
mitochondria. Subsequently, parkin mediates the formation of Lys27-linked 
ubiquitin (Ub) chains on VDAC1. This leads to the recruitment of the autophagy 
receptor p62, which in turn, by binding to LC3, directs damaged mitochondria into 
forming autophagosomes (phagophore). Disruption of this sequential process at 
distinct steps may contribute to the development of PD due to accumulation of 
dysfunctional mitochondria and a concomitant increased cellular toxicity. Taken 
from Wild and Dikic, 2010. 
 
Conequently, dopamine could impair proper mitophagy in our model by downregulating 
VDACs. We could therefore hypothesize that the activation of autophagy described above (as 






the expected removal of damaged mitochondria owing to the lack of VDAC1. The 
simultaneous downregulation of VDACs could be responsible of this misregulation and thus 
cause mitochondrial impairment and consequent neuronal cell death. It is worth to notice, 
however, that the role of VDAC1 in mitophagy has been very recently debated, as Narendra 
and coworkers found that VDAC1 and VDAC3 are dispensable for the recruitment of p62, 
mitochondrial clustering and mitophagy (Narendra et al., 2010). For this reason, we are 
further evaluating autophagy in our experimental conditions and the possible role of VDACs 
in influencing this mechanism, also considering the role played by α-synuclein overall. 
Actually, it has been recently described how α-synuclein overexpression induces 
mitochondrial fragmentation that is rescued by coexpression of PINK1, parkin or DJ-1 (Kamp 
et al., 2010).  
 
A focus on the pool of DJ-1 different species 
The analysis of the literature on dopamine toxicity in SNpc neurons, together with our 
findings on altered mitophagy in dopamine-treated SH-SY5Y cells described above, drew our 
attention to DJ-1, the subject of another targeted study. This protein has multiple functions, 
but its most relevant function seems to be to protect cells from oxidative-stress-related death 
(Uversky and Eliezer, 2009). This function is of primary importance in cells with high 
demand of energy and a strong ROS production, like dopaminergic SNpc neurons. On the 
ground of these considerations we evaluated DJ-1 forms specifically responding to a 
dopamine stimulus. Indeed, under condition of oxidative stress, DJ-1 relocalizes from the 
nucleus to the mitochondrial matrix and intermembrane space and is thought to be 
neuroprotective under such conditions (Zhang et al., 2005). Multiple DJ-1 forms are 
simultaneously present, so that DJ-1 can be better considered as a pool of different species, 
with different modifications and in different amounts. Likely, the composition of this pool 
and the precise balance between different forms is the main factor determining DJ-1 global 
activity. Alterations of this pool, instead of DJ-1 mutations, are expected to play a role in non-
genetic conditions correlated to DJ-1 activity, including idiopathic PD. Indeed, since many 
different DJ-1 forms can be separated on the basis of their pI, it is a common finding that DJ-
1 oxidation, correlated to ageing, PD and Alzheimer‟s diseases (AD), produces an increase in 
DJ-1 species of acidic pH, and a decrease in basic species, so that these conditions are 
characterized by a pool of DJ-1 forms different than that observed in controls. Up to 10 






basic forms (pI 8.0 and 8.4) of SDS-resistant DJ-1 dimer, were reported to selectively 
accumulate in PD and AD frontal cortex tissues compared with age-matched controls (see 
Alberio et al., 2010a).  
While two-dimensional electrophoresis (2-DE) is able to separate modified DJ-1 forms on the 
basis of pI changes, there is little experimental evaluation of DJ-1 modifications to completely 
describe the pool of DJ-1 possible forms and to evaluate the pool composition in a given 
condition (Natale et al., 2010). By performing a meta-analysis of DJ-1 in heterogeneous two-
dimensional electrophoresis experiments we observed changes in this pattern that are 
specifically related to neurodegenerative processes and aging (Natale et al., 2010). The meta-
analysis of proteomic data can provide valuable information pertinent to various biological 
processes (or methods involved) that otherwise remains hidden if a single paper is considered. 
The occurrence of frequently-identified proteins, for instance, may represent common cellular 
stress responses or simply reflect technical limitations of 2-DE, as recently stated by Petrak 
and coworkers in their paper on déjà-vu in proteomics reports (Petrak et al., 2008). However, 
there is such a variability in the 2-DE pattern that it usually prevents the association of each 
isoform to a specific pathological or experimental condition. To this purpose, we analyzed the 
2-DE pattern of DJ-1 in the SH-SY5Y catecholaminergic cell line following a dopamine 
challenge to understand whether specific and reproducible modifications of the DJ-1 isoform 
distribution could be associated to altered dopamine homeostasis. 
Based on the background we got from dopamine exposure of SH-SY5Y cells that has been 
discussed in previous sections, we chose to investigate changes in the 2-DE pattern of DJ-1 
following 24 h treatment with a dopamine concentration (0.1 mM) that did not increase 
intracellular ROS levels, preventively measured using the fluorogenic probe 2‟-7‟-
dichlorodihydrofluorescein diacetate (data not shown). Actually, we wanted to observe an 
effect specifically due to dopamine rather than a generic response to an oxidative challenge. 
Under these conditions, we observed the occurrence of 5 main spots (pI = 5.8, 6.0, 6.3, 6.6, 
and 6.8) progressively numbered from -2 to 2 on going from the acidic to the basic side of the 
pattern, with spot 0 corresponding to the central and most intense one (see Results, Figure 
24). Each spot was observed to be present in all replicates and under both experimental 
conditions, although the relative intensity of the most acidic (-2) and most basic (2) spot was 
significantly affected by dopamine treatment (see Results, Figure 24). In particular, a marked 
reduction of spot 2 was observed, whereas spots -2, fairly visible under control conditions, 






dopamine exposure for each spot with respect to 24 h exposure. As a positive control, we 
treated cells with 1.0 mM H2O2, 15 min. Upon treatment with a strong oxidizing agent a new 
basic form appeared, which in turn was barely detectable following dopamine treatment. 
Conversely, a marked increase in acidic forms was observed, in agreement with what reported 
in the literature (Mitsumoto and Nakagawa., 2001; Mitsumoto et al., 2001). Three main forms 
are reported in the literature in the absence of a dopamine challenge. We were able to evaluate 
the frequency and the intensity of each form thanks to the creation of a meta-gel, i.e., an 
average intensity projection image wherein each pixel stores the average intensity in the 6 
original images at corresponding pixel location (Bandopadhyay et al., 2004; Canet-Avilés et 
al., 2004; Colapinto et al., 2006; Motani et al., 2008). In the absence of dopamine challenge, 
the acidic spot -2 is underrepresented, thus accounting for a specific effect of dopamine in the 
observed increase. Unlike early experiments showing a comprehensive shift of every isoform 
(Bandopadhyay et al., 2004; Mitsumoto and Nakagawa., 2001; Mitsumoto et al., 2001), we 
describe here specific and significant increase of acidic spots (-2 and -1) together with 
decrease of the most basic (2) spot in the 2-DE pattern of DJ-1 upon dopamine treatment.  
Increase in DJ-1 expression may be induced by ROS, and DJ-1 overexpression specifically 
protects against dopamine toxicity (Lev et al., 2008; Lev et al., 2009); more specifically, a 
compensatory upregulation of DJ-1 and parkin has been reported in a A53T α-synuclein 
mouse model treated with the mitochondrial toxin rotenone (George et al., 2010); eventually, 
DJ-1 is indispensable for the survival of dopaminergic neurons lacking the GDNF-receptor 
Ret (Aron et al., 2010). Very recently, loss of DJ-1 has been shown to lead to loss of 
mitochondrial polarization, fragmentation of mitochondria and accumulation of markers of 
autophagy around mitochondria in human dopaminergic cells. Similar to PINK1 and parkin, 
DJ-1 also limits mitochondrial fragmentation in response to the mitochondrial toxin rotenone 
(Thomas et al., 2010). DJ-1 appears thus to display a multi-faceted function that is regulated 
by interaction with cytosolic and mitochondrial proteins (Cookson et al., 2010).  
As a whole, the dopamine-dependent variation observed here may suggest the result of a 
specific post-translational modification functionally linked to an active protective role in 
dopaminergic neurons, rather than reflecting generic oxidative modifications. During the 
preparation of this thesis Guzman and coworkers reported that oxidative stress evoked by 
pacemaking in dopaminergic SNpc neurons is attenuated by DJ-1 (Guzman et al., in press). 
Indeed, SNpc neurons differ from neighbouring dopaminergic neurons (e.g., neurons of the 






neurons take in calcium and release it via L-type calcium channels. This process requires 
energy generated by mitochondria, which in turn causes oxidative stress that is specifically 
counterbalanced by DJ-1. 
 
Validation of proteomic data through an enriched network model 
Although the involvement of most identified proteins with PD pathogenesis is an interesting 
result per se, we tried to build a single, representative network that possibly grouped together 
all the proteins differentially expressed. Instead of validating every single protein by Western 
blot, we applied a different approach by searching for known relationships between the 
identified proteins. Experimentally identified proteins were analyzed in terms of both 
interaction network and GO classification enrichment using PPI spider, a network enrichment 
algorithm based on known protein-protein physical interactions (Antonov et al., 2009). 
Significant (p<0.05) network models were found for proteins that displayed significant 
changes following dopamine treatment, regardless of α-synuclein overexpression, and for 
proteins that displayed significant changes as a consequence of α-synuclein overexpression or 
as a result of the association of dopamine treatment with α-synuclein overexpression (see 
Results, Figure 9). Surprisingly, all proteins were included in two different networks and 
proteins responding to dopamine treatment only are segregated from those showing a 
response to α-synuclein expression. A statistically-significant (p < 0.05) functional 
association to Gene Ontology (GO) classifications was obtained from PPI spider starting 
from proteins grouped as above.  
- NF-κB 
In both cases, bioinformatic analysis revealed that the NF-κB pathway could be 
involved in determining the effects of dopamine treatment and α-synuclein overexpression. 
Accordingly, we transfected β-gal and α-syn cells with the pNF-κB-Luc reporter gene and 
measured the NF-κB-dependent luciferase activity. The basal activation of NF-κB was 
significantly lower in α-syn cells than in β-gal cells, and the expression of the reporter gene in 
β-gal and α-syn cells was dramatically reduced after 24 h dopamine treatment (see Results, 
Figure 11). Dopamine quenched NF-κB activation both in β-gal and α-syn cells similar to 
what reported for the PD-related neurotoxin MPP
+
 (Halvorsen et al., 2002).  
HSP70 is known to be induced by several stress conditions in the nervous system (Calabrese 
et al., 2004; Garrido et al., 2001) and to inhibit NF-κB activation (Malhotra et al., 2002; 






syn cells treated or not with dopamine. HSP70 basal levels are similar in α-syn and β-gal cells 
(see Results, Figure 12). However, dopamine increases HSP70 level 1.5-fold, regardless of α-
synuclein overexpression. Increased levels of the molecular chaperone HSP70 observed here 
in response to dopamine could contribute to the inhibition of NF-κB (Salminen et al., 2008). 
Because the upregulation of HSP70 is only observed after dopamine treatment, the inhibition 
of NF-κB activity by α-synuclein overexpression should be linked to a different pathway, e.g., 
to the increase of GSK-3β levels as recently suggested (Yuan et al., 2008). Noteworthy, the 
NF-κB pathway is less active in all the experimental conditions where higher levels of α-
synuclein are present, either as a consequence of transfection or of dopamine treatment, 
suggesting that α-synuclein could be at least in part responsible for the deactivation of this 
cascade.  
- 14-3-3 
Network enrichment revealed also a central role for 14-3-3 chaperone proteins after 
both dopamine treatment and α-synuclein overexpression. The amino-terminal portion of α-
synuclein shares 40% sequence conservation with molecular chaperones 14-3-3 (Slavotinek et 
al., 2003), suggesting that the two proteins could subserve the same function. Molecular 
chaperones 14-3-3 are particularly abundant in brain, where they comprise ≈1% of total 
soluble proteins. Chaperone 14-3-3 family accumulates in LBs, participates in neuronal 
development and cell growth control, and prevents apoptosis by antagonizing BAD, a 
proapoptotic member of the Bcl-2 family. α-Synuclein binds to many of the same proteins as 
14-3-3, including three proteins known to affect cell viability, protein kinase C (PKC), BAD, 
and extracellular regulated kinase (ERK) (Recchia et al., 2004). α-Synuclein interacts with 
14-3-3, and the interaction between the two proteins produces a 54 to 83 kDa protein complex 
in PD brain. This complex is selectively increased in SNpc but not in cerebellum or cortex. 
Thus, α-synuclein may sequester 14-3-3, leading to a reduction in the amount of 14-3-3 
proteins available to inhibit apoptosis and rendering the cells more susceptible to cellular 
stresses (Recchia et al., 2004). Both 14-3-3 and α-synuclein bind to tyrosine hydroxylase 
(TH), the rate-limiting enzyme in catecholamine synthesis, with divergent consequences: 
activity is stimulated by 14-3-3 but inhibited by α-synuclein (Perez et al., 2002). Therefore, 
lack of available α-synuclein following its sequestration into LBs has been described as a 
cause of increased dopamine synthesis. 
For all these reasons, we measured 14-3-3 levels in β-gal and α-syn cells treated or not with 






treatment. However, 14-3-3 is present in several isoforms with poorly characterized 
specificity of action. Analysis of total 14-3-3 is not informative as a whole, and a detailed 
analysis of changes in δ vs. ε isoforms could be more interesting. Therefore, present data are 
not sufficient to exclude a role for 14-3-3 in our model. Further investigations using two-
dimensional Western blotting and isoform specific antibodies are needed. 
- Apoptosis 
The suggestions obtained from enriched GO categories prompted us to evaluate 
apoptotic cell death in our experimental setting. Dopamine is known to induce apoptosis 
(Cookson and Van der Brug., 2008) and our results are in agreement with this finding (see 
Results, Figure 10, panel A). The basal level of apoptotic cells is not significantly different in 
α-syn cells with respect to β-gal cells (in agreement with cell viability assays) and dopamine 
triggers apoptotic cell death to the same extent in both α-syn and β-gal cells. Remarkably, also 
the percentage of necrotic cells was not significantly affected by α-synuclein overexpression 
(see Results, Figure 10, panel B). Due to the cancerous nature of SH-SY5Y cells, we made 
clear that in all our experimental conditions cell cycle was not affected with the only 
exception of a slight increase in S phase of β-gal dopamine-treated cells, a result that does not 
add anything to our toxicity model (see Results, Figure 14). Although both anti-apoptotic and 
pro-apoptotic properties were attributed to α-synuclein (Cookson., 2006; Cookson and Van 
der Brug., 2008), we did not observe any significant effect due to α-synuclein overexpression 
on the percentage of apoptotic cells. This finding suggests that a 50% increase of α-synuclein 
level does not exert any apoptotic action by itself, nor it increases cell susceptibility towards 
dopamine-induced apoptosis. Rather, the 1.5-fold increase could represent a threshold value 
that discriminates protective from toxic effects (Cookson., 2006). There is clear evidence that 
high levels of α-synuclein can be damaging, but it is equally true that raising its level from 
low to moderate is beneficial. One must also consider that under these different conditions α-
synuclein is present in different molecular forms, from monomeric to heavily aggregated and 
deposited into fibrillar forms, and that the microenvironment of the neuron can modulate both 
baseline expression levels and the aggregation state of α-synuclein (Cookson, 2006). Here, α-
synuclein does not induce any detrimental effect per se, nor it results to be protective at the 
basal level and after dopamine exposure, suggesting that an equilibrium between beneficial 







DOPAMINE RESPONSE OF DOPAMINERGIC CIRCULATING CELLS: THE JURKAT CELL 
MODEL 
 
Basic research can concretely help the improvement of clinical approaches to 
neurodegenerative diseases such as PD, not only by trying to unravel its pathogenetic 
mechanisms but also by looking for possible peripheral biomarkers.  
The second goal of the present thesis can be summarized in three points:  
- substantiate the use of T-cells as an appropriate source of peripheral biomarkers in 
conditions where the dopaminergic system is involved, as it is the case with PD 
(Fasano et al., 2008b).  
- verify if Jurkat cells could be an useful cell culture model to investigate dopamine-
activated biochemical processes in T-cells.  
- find proteins whose level is modified by dopamine in Jurkat cells that might itself 
represent a reporter of dopaminergic functionality at the peripheral level, for instance 
in T-cells of PD patients whether or not stimulated with dopamine. 
 
Jurkat cells express different components of the dopaminergic system. Both D1- and D2-like 
receptors are present, thus accounting for a variety of cellular responses following a 
dopaminergic stimulation. Remarkably, D3(a) and D5 receptors were detected, in addition to 
what was recently reported (Basu et al., 2010). Moreover, they express plasma membrane and 
vesicular transporters, which makes them capable to internalize dopamine and to store it into 
vesicles. Noteworthy, Jurkat cells are not able to synthesize dopamine as they lack TH 
expression (see Results, Figure 26). The body of these results suggests that Jurkat cells posses 
a dopaminergic system similar to the vast majority of T-cells (Pacheco et al., 2009), TH 
activity having been reported in Treg cells only (Cosentino et al., 2007). On this basis, Jurkat 
cells appear to be a suitable model for dopaminergic peripheral cells. 
Dopamine stimulation may elicit both receptor- and transporter-mediated responses. For this 
reason, the dopamine concentration employed here was chosen as the highest possible 
(without affecting cell viability) in order to induce a wide variety of responses. Indeed, D1 
receptors are reported to bind dopamine with a thermodynamic equilibrium dissociation 
constant in the micromolar range (Missale et al., 1998). Although the identification of the 
transduction mechanisms activated by dopamine could be of interest to understand the role of 






our purpose was to identify variations at the protein level that altogether constituted a sort of 
dopamine biosensor. As a matter of fact, dopamine induces a significant change in the Jurkat 
cell proteome (see Results, Figure 27). Specifically, alterations are observed in chaperone 
proteins, glycolytic enzymes and proteins involved in cytoskeleton maintenance. 
Upregulation of stress proteins (e.g., HSP60) and of glycolytic enzymes (e.g. 
phosphoglycerate mutase 1) are commonly identified in proteomics studies and may reflect an 
unspecific response to a generic stress condition (Petrak et al., 2008), or a proteome 
adaptation as a response to perturbation in the protein levels caused by stimuli of various 
origin (Mao et al., 2007). β-Actin itself may behave as a proteome balancer in this view, 
although its deregulation was associated to early stages of pathogenesis in a Drosophila 
model of PD (Xun et al., 2007). The actin isoform pattern is not only modified in its principal 
components, but it shifts towards basic forms. Indeed, the observed upregulation of a basic 
β/γ-actin form after dopamine treatment is confirmed by two-dimensional Western blotting, in 
which a general basic shift is observed (see Results, Figure 29, panel A). Alterations in the 2-
DE pattern of β-actin, with the upregulation of a basic isoform, were also described in 
lymphocytes of PD patients regardless of the therapy (Mila et al., 2009). Noticeably, TCP1θ, 
a subunit of the main actin folding chaperonin CCT (Hynes and Willison, 2000), is 
upregulated in Jurkat cells by dopamine treatment. In general, dysregulation of cytoskeletal 
proteins could be an important common feature of the presymptomatic (or premotor) stages of 
PD that could be involved at the origin of the disorder (Xun et al., 2008). Of course, it would 
be particularly intriguing if the same dysregulation could be detectable at the peripheral level. 
STI1 and TCP1θ, both upregulated in dopamine treated cells, may take part to the formation 
of a large multichaperone complex which recruits further chaperones, such as other TCP1 
isoforms and heat shock proteins (e.g. HSP70, HSC70, HSP90). This complex has been 
demonstrated to play an active role in the protection of dopaminergic neurons (Imai et al., 
2003). Moreover, dopamine treatment of differentiated PC12 cells induces a marked 
upregulation of chaperone proteins, suggesting a protective response towards unfolded protein 
stress (Dukes et al., 2008). Thus, the upregulation here reported might constitute a specific 
response of dopaminergic cells. It should be considered that the low dopamine concentration 
used in this work (50 μM) was not likely to produce the aspecific oxidative stress conditions 
that are observed in neuronal dopaminergic cells, when exposed to higher levels (Alberio et 
al., 2010b; Blum et al., 2000; Gomez-Santos et al., 2003).  






dopamine challenged Jurkat cells comes from the bioinformatic network enrichment 
procedure that clusters in a single network (see Results, Figure 28) all the experimentally 
identified proteins. Additionally, several proteins among those listed here are interactors of 
the 14-3-3 protein family, a set of adaptor proteins that regulate many cellular processes, 
including dopamine synthesis (Pozuelo-Rubio et al., 2004). The analysis of the 14-3-3 
expression pattern by two-dimensional Western blotting represents at the same time a 
validation of the central result coming from the proteome analysis and a deeper inspection of 
the pattern changes suggested by the network enrichment. Although the specificity of action 
of different isoforms is not completely understood, a significant, general remodeling of their 
2-DE pattern is associated to dopamine treatment. Nevertheless, we exclude that the pattern 
remodeling could be associated with the regulation of dopamine synthesis, given the absence 
of detectable expression of TH (see Results, Figure 26). Due to intrinsic limits of the 
resolution of 2-DE and of the specificity of peptide mass fingerprinting, a more detailed 
description of 14-3-3 balance will require further investigation. 
In conclusion, Jurkat cells react to a non-oxidative, saturating dopamine stimulus by inducing 
specific changes in a network of chaperone proteins that are able to interact with 14-3-3 and 
β-actin. This network is known to protect dopaminergic neurons from the dopamine-
associated damage (Imai et al., 2003). These findings substantiate the use of T-cells as an 
appropriate source of peripheral biomarkers in conditions where the dopaminergic system is 
involved, as it is the case with PD . The evidence of a specific response to dopamine, on the 
other hand, suggests that Jurkat cells are a useful cell culture model to investigate dopamine-
activated biochemical processes in T-cells. Eventually, the set of proteins whose level is 
modified by dopamine in Jurkat cells might represent by itself a reporter of dopaminergic 



















1) Evaluate mRNA expression pattern in the four experimental conditions of our model of 
altered dopamine homeostasis (SH-SY5Y overexpressing or not α-synuclein, treated or 
not with dopamine). We aim at the comparison of transcriptomic and proteomic data to 
better evaluate time-dependent effects. 
2) Better characterize the role of VDACs in leading apoptosis and autophagy and describe 
GSK3β activity on VDACs in our model of altered dopamine homeostasis (SH-SY5Y). 
Indeed, ongoing experiments are revealing a role of GSK3β on VDAC2 
phosphorylation and the presence of autophagy, triggered by dopamine treatment. We 
aim at understanding a possible impairment of these processes, in particular of 
mitophagy. 
3) Measure VDACs level in Substantia Nigra pc, comparing post-mortem samples from 




1) Search for a panel of peripheral biomarkers of PD in T-cells.  
We are now performing a proteomic analysis of T-cells comparing those from PD 
patients and from control volunteers aiming at the identification of differentially 
expressed proteins. We have already collected blood samples from EOPD patients, 
LOPD patients, healthy controls, and patients with atypical parkinsonisms, to improve 
specificity of the panel of biomarkers. Although each single protein may be promising 
as a biomarker, it might not have a sufficient predictive power if taken alone. A correct 
balance of sensitivity and specificity may be pursued if a panel of several biomarkers, 
uncorrelated in the general population, is measured. Moreover, inclusion of patients 
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